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The following thesis is structured as follows: Chapter 1 is a literature review that
covers three broad topics: (1) Immune ontogeny in early life, (2) The impact of
HIV exposure on infant health and immunity and (3) EPI vaccines during infancy.
This is followed by four main results chapters (Chapters 2-5). Each result chapter
is written in the style of a publication with a brief introduction giving a rationale
for the study, a methodology, results and discussion sections. Chapter 5 includes
already published work (see Declarations) with some minor modifications. The final
chapter is a summary and conclusions chapter.
1
Abstract
Background. In some regions of Sub-Saharan Africa, up to 30% of newborns are
born to mothers infected with human immunodeficiency virus (HIV). Maternal
antiretroviral treatment (ART) has reduced vertical transmission to lower than
1%. Despite the success of prevention of mother-to-child transmission (PMTCT)
programmes, a large number of children born to these mothers are exposed to HIV
and antiretrovirals (ARVs) in utero yet remain uninfected. These individuals, known
as children who are HIV-exposed and uninfected (cHEU), succumb to higher rates
of disease morbidity compared to children who are HIV-unexposed (cHU) which
suggests altered immunity in the cHEU. Differences in the numbers and function
of cells of the innate and adaptive immune system have been documented in cHEU
though not consistently. While vaccine-induced antibody responses are robust in
cHEU, data on potential cell mediated perturbations to vaccine antigens remains
conflicting. This is in part due to inherent inter-cohort variation and differences
in ART therapy strategies, feeding practices between cohorts and the assays used
measure cell-mediated responses. We leveraged two independent cohorts from Nigeria
and South Africa of mother-infant pairs receiving antenatal and postnatal care all
under Option B+ PMTCT. All HEU infants received pre-exposure prophylaxis for 6
weeks and the majority were exclusively breast-fed until 6 months of age. We applied
the same assays in both cohorts to test the hypotheses that HEU have altered T cell
immunity compared to HU controls and distinct transcriptomic signatures at birth.
These were tested in three distinct aims:
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1. To identify transcriptional signatures at baseline that delineate cHEU from
cHU
2. To compare the expression of surface marker broadly defining activated or
regulatory phenotypes —and the expression of intracellular markers of T cell
function between cHEU and cHU over the first 9 months of life.
3. To characterise how differences in the immunising strains of Bacille Calmette-
Guérin (BCG), the first vaccine received in these infants, impacts T cell
immunity to both mycobacterial and non-mycobacterial antigens in cHEU and
cHU.
Methods. Two birth cohorts from Jos, Nigeria and Cape Town (CT), South Africa
were recruited into this study as part of a larger parent study that aims to identify
biological determinants of protection from mother-to-child transmission of HIV
(Innate, Adaptive and Mucosal Immune Responses in Infants/INFANT study: HREC
285/2012). Infant blood was collected at several time points from birth to 36 weeks
of life for immunological assays. Whole blood, collected at birth was preserved
in PAXgene fluid for downstream messenger ribonucleic acid (mRNA) transcript
analyses. Other whole blood samples were fixed and cryopreserved either directly ex
vivo or after re-stimulation within 1 hour of phlebotomy with BCG, Tetanus Toxoid
(TT), Bordetella pertussis (BP) antigens and Phytohemagglutinin (PHA). Multi-
parameter flow cytometry was used to measure batched whole blood samples for (i)
markers of T cell regulation and activation directly ex vivo, markers of T cell gut
homing and proliferation—a proxy for HIV susceptibility, and (ii) vaccine-induced
Th1 cytokine expression (IFN-γ, TNF-α, IL-2) and memory maturation. Cytokine
responses were profiled for polyfunctionality by SPICE analysis and complemented by
the COMPASS algorithm. Transcriptional profiling of whole blood at birth was done
by RNA sequencing and differentially expressed genes were reported for absolute
fold change of normalized counts >1.5 with FDR set at 0.05 using the DESeq2
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package in R. Gene-set enrichment analysis (GSEA) was used to identify enriched
or repressed gene pathways for absolute normalised effect sizes >1.5 with FDR set
at 0.05. Longitudinal analyses used a mixed effects ANOVA with time and HIV
exposure as explanatory variables. Cross-sectional analyses comparing HIV exposure
groups used Wilcoxon Ranked Sum Test, with p<0.05 considered significant after
multiple correction adjustment by Holm’s step-down method.
Results. Aim 1: A small set of DEGs were found between HEUs and HU groups
at birth, 3 of which were upregulated and 12 that were downregulated. Among the
upregulated genes, two are homologues of the arrestins ARRDC4 (2.3 fold, adjusted
p-adj<0.001) and TXNIP (1.4 fold, p-adj<0.001). Gene-set enrichment analysis
however, showed no significant enrichment or suppression of gene pathways in HEUs.
Aim 2: HIV/ARV exposure did not have an interaction effect with age (all time
points) in explaining the frequencies of T cell markers ex vivo in a mixed-effects
model. In cross-sectional unadjusted analyses however, trends towards increased
median frequencies of markers of activation in the HEU group compared to HU
controls were observed for specific ages: at birth (%CD8+HLA-DR+: 0.12 vs. 0.01,
p=0.05), at week 7 (%CD8+CD25+: 0.13 vs. 0.04, p=0.01 and %CD8+HLA-DR+:
0.84 vs. 0.07, p=0.01) and at week 36 (%CD8+CD25+: 0.52 vs. 0.03, p<0.001
and %CD8+HLA-DR+: 0.81 vs. 0.17, p=0.003). When adjusting for multiple
comparisons, only CD25 expression remained significant on CD8+ T cells at week 36
(p-adj=0.04). The magnitudes of cytokine responses by T cells to vaccine antigens
did not differ between HEU and HU infants however transient differences in the
polyfunctional profile of cells was observed at week 1 for mycobacterial-specific Th1
profiles in CT infants (p=0.002) by SPICE analysis. There were later differences at
week 7 for BP-specific Th1 profiles in Jos infants (p=0.01) and at week 36 for BP-
specific Th1 profiles in CT infants (p=0.03). The more robust COMPASS algorithm
only detected a trend towards increased polyfunctional scores to BP responses in CT
infants at week 36 (p=0.03).
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Aim 3: BCG immunising strain impacted the magnitudes and quality of responses to
mycobacterial and non-mycobacterial vaccine antigens irrespective of HIV exposure
status. Most significantly, at week 7, BCG-Denmark induced higher mycobacterial-
specific frequencies of CD4 Th1 cytokines compared to Bulgarian (p<0.001) and
Russian strains (and (p<0.001). BCG-Denmark induced greater triple cytokine
profiles to mycobacterial antigen compared to Bulgarian (p<0.001) and Russian
(p<0.001) strains in SPICE analyses and the resulted were confirmed by COMPASS
algorithm polyfunctional scores. Furthermore, BCG-Denmark significantly enhanced
antigenicity to TT and BP vaccines.
Conclusion. Transient differences exist in the frequencies of CD25 expressing CD8
T cells between HEU and HU groups, however other readouts of immunity suggest
that in the context of effective PMTCT and exclusive breast feeding practices, HEU
infants are indistinguishable from their HIV unexposed peers.
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1.1 Ontogeny of the human immune system
The concept of immune ontogeny—the evolution of the immune system from an
immature state to that of a mature or adult-like state—is fundamental to under-
standing immunity in early life [1]. Much of what is known about immune ontogeny
has been derived from studies using animal models, given the limitations of sampling
human fetuses and neonates. The development of the immune system of can be
broadly divided into two phases each with their own unique challenges. The pre-natal
phase of immune development requires the maintenance of fetal-maternal tolerance,
whilst simultaneously adapting to in utero pathogenic challenge whereas post-natal
phase requires the rapid adaptation to a host of environmental and pathogenic
challenges [1]. Pre-natal immunity begins with the protection of embryonic cells
via innate immune processes such as the recognition of foreign pathogen associated
molecular patterns (PAMPs) in a process described as cell autonomous immunity
(CAI) [2]. Immune subsets that display adult-like characteristics are detectable
in human fetal tissues as early as 5 weeks of gestation [3], however these cells in
the fetus are functionally distinct from adults [4, 5, 6]. Several key observations
demonstrate that post-natal immunity is age-dependent; firstly innate responses to
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PAMPs stimuli mature from birth through the neonatal period to about 1 year of
age [7, 8, 4, 9], secondly T and B cells at birth and during the neonatal period are
of a naive-like phenotype [10, 11] suggesting limited antigen exposure in utero and
thirdly a change the shift from Th2-like polarisation in early infancy towards a more
balanced Th1/Th2 phenotype [12, 13].
1.1.1 Factors that drive immune ontogeny in early life
The development of immunity in early life is determined by the sum total of both
abiotic and biotic factors. Some of the biological factors that shape immune on-
togeny during infancy is discussed here. Amongst others they include host genetics,
environmental microbes, the initial colonising microbiome, breastfeeding practices
and maternal infections during pregnancy. These factors act to influence immune
tolerance, allergic immunity and immune responses to pathogens and vaccines in
early life [1].
Environment
Population differences in susceptibility to disease are well-known. These differences
reflect intrinsic factors such as host genetics of innate immune sensors [14, 15] as
well as extrinsic factors such as environment which impact on immune programming
particularly in early life [1, 16]. Distinct cytokine expression patterns in response to
toll-like receptor (TLR) stimuli have been observed in newborns of different racial
backgrounds [17, 18] which support a role for host genetics in innate immunity. A
recent study on the ontogeny of innate responses between Asian and Caucasian
infants living in the same environment, found that the initial divergent patterns in
cytokine expression at birth eventually converged by 2 years of age [18] suggesting that
intrinsic factors can be over-ridden by environmental cues. When innate responses
were compared in 2 year old infants from four different continents, a unique hypo-
responsiveness to TLR4 and and TLR7/8 stimuli among South African was found
17
compared to European, North and South American populations [19] underscoring the
role of environment in driving responses to microbial stimuli. Adaptive responses are
also driven by environment as shown in Bangladeshi and American infants followed
up from birth where significant divergence was observed at 2 years of age. Elevated
IL-8 and cytotoxic T cell responses to polyclonal stimulus were the defining feature
of Bangladeshi infants at 2 years of age, whereas at birth, T cell function was
indistinguishable between the two cohorts [20]. The environments in the tropics are
considered as being uniquely microbial rich, and the inhabitants of these areas suffer
a disproportionate burden of infectious diseases compared lattitudes further away
from the equator [21]. Compounding this, are factors related to limited resource
settings where poor nutrition, hygiene and lifestyle affect infant health. The ‘hygiene
hypothesis’ [22] proposes that continual exposure to microbes in early life, educate the
immune system towards a Th1-biased phenotype and away from a Th2 phenotype
that favours allergic immune responses [23]. Consistent with this is hypothesis
is the epidemiological data showing an emergence of auto immune disorders and
allergies in infant populations from urbanised Western settings—assumed to be less
exposed to microbial stimuli [24]. Helminth infections are endemic in the tropics
[25, 26, 27] and these infections are associated with Th2 skewing [28] and other
immunomodulatory effects including impaired responses to vaccination, increased
susceptibility to infections and a suppression of allergy responses [29, 30, 31, 32, 33,
34]. This may explain in part why BCG—a potent inducer of Th1 immunity—has poor
efficacy in the tropics [35], where BCG-induced Th1 responses are lower compared to
populations further away from the tropics [36, 32]. Given that helminth infections are
common for pregnant women in helminth-endemic areas [37], it has been suggested
that in utero sensitisation to helminth antigens pre-disposes newborns to other
infectious burdens [38, 30, 39], alters their vaccine responses [30, 40] and perturbs
immune subsets [41]. In Uganda, maternal hookworm infection was associated with
increased IL-10 cytokine responses to Tetanus Toxoid vaccine in their infants in
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a large observational study of 1500 mother-infant pairs [40]. Some studies have
demonstrated that treating helminth infections improves immune responses to non-
helminth [42, 43], leading to suggestions that helminth treatment during pregnancy
may restore vaccine responsiveness in infants [37]. In a randomised controlled trial
however, maternal anti-helminth treatment during pregnancy did not improve infant
BCG immune responses but did result in reduced IL-5 and IL-13 responses for
Tetanus Toxoid vaccine [44]. In early life, the immune system is Th2 biased, which
is thought to contribute to the increased vulnerability to pathogens that typically
require Th1 responses for clearance. Without any interventions, environments that
delay the ontogeny of Th1/Th2 balance by skewing the immune system to a Th2
phenotype may render infants vulnerable to infection.
Microbiome
The developing fetus was assumed to be sterile, free from antigen exposures that could
imprint on immune development. This dogma has since changed, and the amniotic
fluid that surrounds the fetus is recognised as being non-sterile [45] with one study
reporting that the placenta harbours a distinct microbiome [46]. The first post-natal
exposures come from the transfer of microbial communities from the mother to child
during the birthing process [47]. The most significant determinant of the colonising
microbial profile in neonates is the initial maternal innoculum—determined by the
mode of delivery [48]. Microbial communities established after C-section delivery
resemble those of the maternal skin [49] and hospital related-bacteria [50]—considered
unfavourable to the health of the infant [51, 52]. Vaginal delivery in contrast results
in colonisation of beneficial Bifidobacterium species [47, 53], which are associated
with reduced incidences of respiratory tract infections [54, 55]. In addition, feeding
practices (breast-milk vs. formula, cessation of breast-feeding, introduction of solids
etc.), the use of antibiotics (infant and/or maternal) determine the kinds of microbial
communities that eventually colonise much of the neonatal gastrointestinal tract
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[47, 56]. There is growing evidence that the profile of early microbiome and any
disruptions thereof, impacts immunity to allergens, pathogens and vaccines [57, 58,
59, 60]. The pre-vaccination composition of gut microbial species was a significant
determinant of Rotavirus vaccine antibody responders in a study of Ghanaian infants
[60]. In a study of Bangladeshi infants, higher relative abundances of Bifidobacterium
longum species was associated with elevated T cell responses to BCG, Tetanus-specific
and Oral Polio vaccines [61]. Other Bifidobacterium species are positively associated
with fecal Polio IgA antibody levels [62]. The cross-talk between gut microbes and
the gut immune system determines the Th1/Th2 balance in early life [63] with
specific microbial taxa and their metabolites impacting cytokine responsiveness to
microbial stimulations [58]. A specific carbohydrate molecule absent in a mutant
commensal Bacteroides fragilis species was sufficient to skew systemic responses to
a Th2 phenotype in a mouse model [63], highlighting the importance of specific
microbial communities in shaping early Th1/Th2 balance. Feeding patterns in the
first year of life impact the microbial ecology of the infant gut. Breastmilk—in
addition to its nutritional and passive immunity benefits—promotes the colonisation
of healthy gut microbes to the infant [47, 64, 65]. A Swedish study found that
the cessation of breast-feeding was significant in determining whether infant gut
microbiome resembled that of an adult at 12-months of age [47]. In animal models
significant changes in immune profiles have been observed depending on the feeding
pattern. The dynamics of serum cytokines differ between formula-fed (FF) and
breast-fed Rhesus macaques, with higher pro-inflammatory cytokines are detected in
macaques at 4 months of age [64]. This coincides with a preferential accumulation
of Lactobacillus species and a reduction of Bifidobacterium species compared to
formula-fed infants [64]. Another study in Rhesus macaques found that breast-fed
infants had significant elevated relative abundances of Provotella, Clostridium and
Lactobacillus species in their guts compared to formula-fed infants [65]. Importantly,
this study showed that CD4 T helper cell memory populations cells in peripheral
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circulation developed quicker and were significantly elevated up to 12 months of
age in the breast-fed group. These studies demonstrate how diet shapes the infant
microbiome with consequences for mucosal immune ontogeny in the first year of life.
In summary, the colonisation of the newborns by specific microbial communities
by birth mode, feeding practices represent an immunological imprint that determines
how the immune system responds to antigen stimuli.
Chronic maternal infections
Early life immunity is impacted by maternal infections during pregnancy—even in
babies that do not experience vertical transmission of the etiologic agent. Evidence
is accumulating that the immune ontogeny of these "uninfected yet unaffected" [66]
babies differ significantly from those born to healthy mothers. Incidences of helminth
infections amongst pregnant women in some populations can reach as much as 30% [67,
68]. As previously described maternal helminth infections have immunomodulatory
effects in the infant. Other chronic infections during pregnancy—particularly for
tropical regions—with consequences for neonatal and infant immunity include Try-
panosoma cruzi—the etiological agent of Chaga’s disease [69], Plasmodium falciparum
which causes malaria and HIV [66]. Infection with Plasmodium falciparum sensitises
fetal T and B cells [70, 71, 72] with effects on neonatal innate responses [73, 74, 71]
however, these do not translate to alterations to cell-mediated responses to Tetanus
vaccine for example [75, 76]. Infection with Trypanosoma cruzi during pregnancy on
the other hand, alters the ontogeny of antibody IgG responses against hepatitis B
in infants with vertical transmission compared to infants born to uninfected moth-
ers [77]. Furthermore, maternal Trypanosoma cruzi infection during pregnancy was
associated with an enhancement of purified protein derivative (PPD) Th1 responses
in infants that did not experience vertical transmission [77]. HIV infection remains
high amongst pregnant women in Sub-Sahran Africa [78]. Despite a reduction in
transmission rates due to antiretroviral treatment during pregnancy, infants born to
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HIV infected mothers experience an increased burden of infectious disease morbidity
that suggest a perturbed immune profile and/or immune ontogeny [79]. Studies
on the ontogeny of immunity among children who are exposed in utero to human
immunodeficiency virus/antiretrovirals have only recently been considered and the
ontogeny of T cell phenotypes and function these infants is the focus of this thesis.
1.2 Immune differences between children who are HIV-
exposed yet uninfected and HIV unexposed
Prevention of mother to child transmission programs (PMTCT) has drastically
reduced vertical transmission rates of human immunodeficiency virus (HIV) from
approximately 30% during the pre-antiretroviral treatment (ART) era [80] to lower
than 1% in some countries [81]. Infants who have escaped HIV transmission in utero
or postnatally are termed children who are HIV-exposed and uninfected (cHEU)
infants [82]. The numbers of cHEU are increasing yearly and account for as many
as 30% new births in Sub-Saharan Africa [78]. Although HIV-uninfected, these
infants are disproportionately affected by infectious disease morbidity and mortality
compared to children who are HIV-unexposed (cHU) [83, 84, 85, 86]. Notwithstanding
the social disadvantages to being born in an HIV household, a number of biological
factors are implicated in the poorer health outcomes in these infants [79]. This
section will review the evidence for disproportionate infectious morbidity burden
among cHEU and the potential immune perturbations in the infant that may account
for this.
1.2.1 Infectious disease burden
Prior to the widespread availability of ART programmes for pregnant women, a
large number of infants born to HIV-infected mothers died within the first year of
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life [87, 78]. In the era of PMTCT, cHEU are still disproportionately affected by
infectious disease compared to children who are HIV unexposed (cHU) [88]. Common
infections observed in cHEU include those caused by bacterial, fungal and viral
agents Epalzae631, mussi2010lower. Group B Streptococcus (GBS) infections in
newborns and young infants can cause complications like sepsis and meningitis if
left untreated [89, 90]. Increased incidences of GBS among HEU neonates and
young infants have been found in both European [91] and African cohorts [92]. In a
Belgian study assessing GBS incidence and clinical presentations among newborns
at a referral hospital between 2001 – 2008, found that the risk of all GBS infections
were higher in HEU compared to HU controls (RR = 19.6, 95% CI; 7.5 – 51.7),
in particular late-onset GBS infection (RR = 125.2, 95% CI; 26.3 – 620.2) [91].
Importantly these observations were in cohorts where PMTCT programmes were in
place in accordance to local guidelines [93]. In South African infants annual estimates
for the risk of invasive GBS infections between 2004 and 2008 were 2.25-fold higher
among HEUs compared to HUs [92]—a period in which PMTCT programmes were
not widely adopted. Another South African study found that risk of death due
to Invasive pneumococcal disease (IPD) in infants younger than six months was
highest among HEU compared to HU controls (adjusted RR = 1.76, 95% CI; 1.09 –
2.85) [84].
Lower espiratory tract infections are also commonly reported for HEUs [94, 95,
96, 83]. A survey of cHEU in France between 2002 and 2010 showed that 40% of
infections among this group that led to hospitalisations or death were a result of viral
or bacterial broncho-pulmonary infections [97]. Crucially, that survey of nearly 7000
neonates excluded those were that were breastfed. Exclusive breastfeeding in the first
months of life has been shown to reduce infectious morbidity in HEUs [98]. Current
WHO guidelines recommend HIV-infected mothers practice exclusive breastfeeding
until at least six months of age [99]. Two earlier reports, prior to this adoption
of WHO recommendations, found that the incidences of lower respiratory tract
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infections (LTRI) are higher among cHEU infants compared to cHU particularly
within the first six months of life [100, 83]. A birth cohort assessing the incidence,
severity and risk factors for pneumonia in the first year of life showed that the
incidence rate ratio for pneumonia among cHEU was 1·38 (95% CI; 0·91 – 2·03)
and a third of pneumonia cases in these infants required hospitalisation [100]. In
that study, HIV exposure was a significant risk factor for severe pneumonia (RR =
4.04, 95% CI; 1.51 – 10.80) whereas the introduction of any formula feeding prior
to six months was not [100]. In a Botswana study, the risk ratio among cHEU
presenting pneumonia at a tertiary hospital was 1.8 (95% CI; 1.27 – 2.64, p=0.001)
with in-hospital mortality 4.31 (95% CI; 1.44 – 12.87, p=0.01) [83]. In that study,
47% of cHEU in failed pneumonia treatment compared to 24% of cHU. Of note, was
that breastfeeding rates were low among HIV-infected mothers, therefore the elevated
risk of pneumonia may be related to inadequate passive immunity provided by breast
milk. In a retrospective study of Kenyan infants, followed monthly over the first year
of life, breastfeeding was found to be associated with a 47% lower risk of pneumonia
among HIV-exposed infants compared to infants that were never breastfed (hazard
ratio = 0.53, 95% CI; 0.3 – 0.73) [101]. Surprisingly, this reduction in risk was
independent of maternal CD4 and viral load in women that were not on antiretroviral
treatment. Thus, the practice of breastfeeding—which HIV infected mothers have
historically opted against for fear of transmitting HIV to their babies—is a significant
determinant in reducing the risk of lower respiratory tract infections. Bordetella
pertussis (BP) is the cause of whooping cough in children [102] and has been shown
to disproportionately affect cHEU in both incidence and severity in some studies [103,
104]. In both South African and Zambian cohorts, the incidence of BP infection and
rates of hospitalisation as a result of BP infection were slightly higher in cHEU [103,
104], while one study showed that HIV exposure was not a risk factor BP infection in
a South African setting [105]. In a TB endemic setting, similar rates of Mtb infection
(as measured by IFN-γ release assays in blood) were observed between HIV infected
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children and HEU—despite being BCG vaccinated and having received preventative
Isonaizid therapy [106]. This suggests that HEU children are equally vulnerable
to Mtb infection as HIV-infected children. Increased rates of Mtb infection among
HEUs may be driven by exposure to household TB contacts due to maternal HIV-TB
co-infection. In Uganda, cHEU under 5 years of age had higher odds of Mtb infection
compared to cHU (OR = 21.2, 95% CI: 2.2 – 204.7, p=0.008) [107]. These HEU
children in addition were underweight highlighting the need for adequate nutrition
for this vulnerable population. Infectious burden among cHEU is not limited to
bacterial infections. HIV-exposed children are at a higher risk for cytomegalovirus
(CMV) infection during infancy compared to their unexposed counterparts [108].
Even in pregnant women on ART, increased incidences of congenital CMV infection
are reported in their HIV-exposed uninfected newborns [109, 110, 111]. In summary,
cHEU experience more bacterial-related and to a lesser extent viral infections than
cHU. Many of the bacterial infections are lung-related, more severe and often fail
treatment compared to cHU particularly for infants who are not breastfed. Combined,
these studies suggest that altered immunity exists in cHEU that is likely ineffective
in mounting protective responses that would limit or prevent childhood infections.
This remains a relatively underexplored area of investigation.
1.2.2 Differences in immune cell numbers and function
Several innate and adaptive immune abnormalities have been documented in cHEU [79].
The innate immune system is the first line of defence against foreign pathogens and a
number of studies have shown differences in both innate cell frequencies and function
between cHEU and cHU groups [79]. Absolute neutrophil and monocyte counts in
the peripheral blood have been shown to be lower in cHEU [112]. In a study by
Bunders et al., [112], total lymphoctye counts in HIV exposed babies were positively
associated with CD4 counts in their HIV infected mothers. This association with
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maternal neutrophil counts have been shown to be consistently lower than cHU up
to 8 months of age [112], which suggests an increased migration of these cells from
the periphery to sites of inflammation among cHEU. Myeloid-derived dendritic cells
(MDDC) have been shown to be elevated at birth in HEU compared to HU controls,
but comparable from 3 – 12 months of age [113]. In addition to differences in cell
numbers, innate cells respond differently between cHEU and cHU groups to a number
of innate cell stimuli [114, 115] suggesting altered function. For example, monocytes
and dendritic cells from cHEU produce elevated pro-inflammatory cytokines IL-6
and TNF-α in response to stimulation with bacterial pathogen associated molecular
patterns (PAMPS) up to at least 6 weeks of age [114]. Cord blood mononuclear cells
(CBMC) from HEU newborns stimulated with Staphylococcus aureus Cowan (SAC)
produce significantly less IL-12 than SAC-stimulated CBMC from HU newborns [115].
Natural killer cells (NK) are a cytotoxic subset of the innate immune system capable
of recognising virally infected cells [116]. A Kenyan study found that despite their
lower frequencies at birth, NK cells from cHEU were functionally superior to cHU
in cytotoxic killing assays in vitro, however this enhanced function was lost by 6
months of age [117]. In summary, innate immunity in the HEU is characterised by
differences in cell numbers compared to HU and an increase in innate cells function
during early infancy, however, this enhanced ability appears to be lost later on.
CD4 and CD8 T cells form part of the cellular immune response to pathogens
exerting a number of functions after the engagement of the T cell receptor (TCR)
to antigen on human leukocyte antigen (HLA) molecules. A number of studies
report that HEU infants and children have lower CD4 and CD8 T cell counts
compared to their unexposed peers [118, 119, 112, 120]. A study of HEUs stratified
by antiretroviral exposure status (n=1820; maternal ART use during pregnancy and/
or infant prophylaxis vs. n=351; no ARV) [121] found a trend towards decreased
CD4 and CD8 T cell counts in the ART-exposed group in the first two months of life
which became significant in the subsequent 6–24 month period [121]. This suggests
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that exposure to ART in utero or perinatally has possible implications the numbers
of functional T cells in early life. These differences in T cell numbers persist to
pre-adolescence [120], though not observed consistently [118]. Lower T cell counts in
the blood of cHEU may be related to reduced thymic output or reduced progenitor
function. A study by Nielsen et al., [119] found reduced CD4+ naive and memory
subset counts in babies born to HIV-infected mothers on ART (the majority: 18/20
with CD4 counts >200/µL) suggesting that treatment during pregnancy does not
normalise CD4 T cell counts in HIV exposed babies. Overall, there is evidence that
a number of hematological parameters are reduced in infants born to HIV infected
mothers—even on suppressive ART. This reduction in immune cell counts is partly
associated with maternal CD4 counts and is more severe in the case of maternal
lymphophenia. The clinical significance of these reduced cell counts on the health of
the HEU is as yet unclear.
Whilst immune cell numbers may be important, the effector functions of these
cells in cHEU may be more relevant [79]. Recently, a growing number of studies on
cellular mediated immunity in cHEU are focused on responses to vaccination which
is covered in the next section.
1.2.3 Antibody responses
Some of the more common morbidities observed in cHEU are against vaccine pre-
ventable diseases [84, 106, 104, 103] suggesting that this group fail to mount effective
immunity following vaccination and therefore are at increased risk for acquiring
infection. In addition to the nutritional benefits provided by breast milk, breast-fed
infants are provided with passive immunity which lower the risk of infectious mor-
bidity and mortality [122, 98]. HEU neonates have lower levels of passive immunity
against vaccine-preventable diseases compared to HU neonates [123] which under-
scores the need for effective immunisation in this group. In a South African study
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measuring antibody levels to vaccine preventable diseases (Haemophilus influenzae
type b, Pneumococcus, Bordetella pertussis, Tetanus and Hepatitis) found that birth
antibody titres were lower among HEU compared to HU groups, but routine vacci-
nation resulted in comparable antibody levels [123]. In general, antibody responses
to most routine vaccines are robust among cHEU who have received the full course
of booster vaccinations and the vast majority maintain sero-protective levels to at
least two years of age [114, 124, 123, 125].
1.2.4 Cell-meditated responses
Cell-mediated immunity (CMI) refers to the ability of immune cells to respond to
antigenic stimulation by proliferating, exerting cytotoxic effects or producing effector
molecules such as chemokines and cytokines. There is no broad consensus in the
literature on whether cell-mediated immune reponses are perturbed in cHEUs. Prior
to PMTCT programmes being widely adopted, comparisons of HEU and HU groups
were heavily confounded by factors related to the health of HIV-infected mothers,
including high viral loads and low CD4 counts. The impact of maternal and/or
neonatal ART use on cell-mediated responses can only be assessed by observational
studies, however limited sample sizes mean that only a few studies have directly
assessed this. As more countries adopt standard PMTCT programmes like Option
B+, HEU cohorts are likely to become more homogenous with respect to the use
of ARV regimens and the overall benefits of antenatal and post-natal care provided
by PMTCT programmes to the health of mother and child. Nevertheless, the
interpretation of even recent CMI studies is difficult given other confounders related
to experimental methodology, the stimulating antigen, geographical and age-related
differences of the cohorts studied (Table 1.1). As pre-exposure prophylaxis during
pregnancy expands in South Africa, more data on the effects of ARVs, in the absence
of HIV, on foetuses and infants may accumulate.
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Cellular responses to mycobacterial antigens
Much of the data on cell mediated immunity in cHEU have come from studies
evaluating responses to BCG or mycobacterial antigens [126, 40, 127, 128, 129, 130,
131, 132]. This is because HIV endemic regions in sub-Saharan Africa suffer the
added burden of TB disease [133], meaning that many cHEUs in these regions are
repeatedly exposed to Mycobacterium tuberculosis (Mtb), and therefore at risk for
TB disease [134, 107]. Although correlates of protection against TB disease remain
undefined, understanding vaccine immunity against Mtb as well as immunity to Mtb
itself in cHEU, may provide insight as to whether they maybe disproportionately at
risk for TB disease. Typically, the read-out from these studies is either intracellular
cytokines or soluble immune mediators released into culture media after short- or
long-term incubation with antigen. In studies comparing cellular responses between
HEU and HU groups following long-term (>24 hrs) culture with mycobacterial
antigen, differences or lack thereof exist depending on the read-out. For example, the
frequencies of total blasting T cells—as measured from light scatter properties by flow
cytometry—are not impacted by HIV exposure status [129], whereas the frequencies
of mycobacterial-specific proliferating cells—as measured by Ki67—following long-
term culture, two studies found no differences between HEU and HU groups [40, 126]
with one study showing that differences were age-dependent (greater proliferation
among HEUs at 16 weeks but not 6 weeks) [128]. In a study characterising T cell
function in HEUs whose mothers received ART during pregnancy and had CD4 counts
>200 cells/mm3, Kidzeru et al.,[128] found reduced proportions proliferating T cells
producing any 3 combinations of IFN-γ, IL-2, Th17 or IL-13 in response to in vitro
BCG stimulation at 6 and 14 weeks of age. Of note was that rates of lower respiratory
tract infections in this study were twice that of the HU control group suggesting a
possible link between altered immune responses and susceptibility to infection. Other
studies have found no differences in polyfunctional T cells (simultaneously producing
3 or more cytokines)[127, 131], which are implicated in protective immunity [135,
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136, 137]. A distinguishing feature of the lymphoproliferation assay by Kidzeru et
al., [128] was the addition of PMA/ionomycin to BCG-stimulated culture in the final
4 hours of the assay, where others have used either Staphylococcus Entero-toxin B
(SEB) [126] or no mitogenic re-stimulation [129, 130]. Thus, the results of long-term
in vitro assays are confounded by the use of superantigen or mitogen in addition
to the primary antigen stimulus. For levels of soluble mediators after long-term
culture, TNF-α and GM-CSF were found to be elevated only in BCG-stimulated
cultures of HEUs whose mothers who showed Mtb sensitisation by Quantiferon Gold
testing [130], suggesting that maternal mycobacterial exposure may preferentially
prime BCG responses in the HEU infant. Maternal BCG immunisation however does
not appear to enhance infant responses to Mtb, as shown by a large study of 1500
Ugandan infants, where maternal BCG scar (indicating prior immunisation) was
associated with lower infant IL-5 and IL-13 responses to Mtb secreted crude culture
filtrate proteins (cCFP) [40]. In the same study, cCFP responses in the infant did
not differ by maternal HIV status among HIV-uninfected infants [40].
Fewer studies have evaluated CMI to mycobacterial antigens between HEU and
HU using short-term in vitro assays [127, 131]. The whole blood assay is a standard
for short-term CMI measurements, where whole blood is incubated directly with
antigen [138]. Unlike PBMC based assays, no isolation of cells is required, a logistical
advantage for field studies where often the laboratory is not easily accessible. In
addition, whole blood more accurately reflects physiological conditions in vivo, with
appropriate growth, co-factors and cells for antigen processing and presentation
[139]. The results from whole blood intra-cellular cytokine staining (ICS) assays
suggest that HEUs are immune competent. For example Ugandan infants who were
BCG-vaccinated at birth had total intra-cellular cytokine frequencies responding
PPD at 3 months post vaccination [127] and a South African study showed higher
frequencies of BCG-specific CD8 T cells positive for IFN-γ among HEUs compared to
controls only at the 6-month time point [131]. A criticism of these two ICS studies is
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that no correction for multiple comparisons was performed which may have negated
the observed differences between HEU and HU groups. Furthermore, Mansoor et
al., [131] did not report on potential maternal confounding variables such as CD4
counts and viral loads, however, as mentioned by the authors routine ART was not
available at the time of study. In summary the impact of HIV exposure on infant
cellular immunity to BCG is confounded by infant age, the cellular assays used and
their readouts as well as maternal confounders.
Cellular responses to mitogens
One of the more consistent findings of cell mediated responses in the HEU is
the impairment of a number of effector cytokines after in vitro stimulation with
superantigen or mitogen (Table 1.1). After six-day stimulation with staphylococcus
enterotoxin B (SEB), Kidzeru et al., [128] showed that the capacity to produce
multiple cytokines at a single-cell level was diminished compared to HUs, with
significant differences in proliferating CD8 cells expressing both IFN-γ and IL-13.
This impaired cytokine production to SEB is supported by studies measuring total
CD4 cells, where lower frequencies of cells expressing IFN-γ, IL-4, TGF-β and IL-10
after 72 hours of stimulation [140] and IL-2 and TNF-α after 12 hour stimulation are
observed in HEU compared to controls [127]. Lower cytokine responses in HEU cell
cultures stimulated with the lectin PHA have also been observed for IFN-γ, TNF-α
and IL-2 [130, 132] suggesting that impaired cytokine production may involve other
immune subsets beyond T cells. Interestingly, PHA stimulation shows comparable
frequencies of proliferating T cells between HEU and HUs [129, 130] whereas SEB
enhances T cell proliferation among HEUs albeit after secondary stimulation with
PMA/ionomycin [128].
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Cellular responses to other vaccine antigens
CMI studies to non-mycobacterial vaccine antigens that directly compare HEU and
HU groups have been limited. Two studies have measured cellular responses to
Tetanus Toxoid [40, 127] and one to Pertusssis antigens [128]. Altered cytokine
responses to Tetanus in the HEU have been observed for long term in vitro stimulation
assays [40] but not in short-term assays [127]. A large Ugandan study measuring
cellular responses to Tetanus Toxoid in 12-month old infants, found reduced levels of
IFN-γ, IL-5 and IL-13 in HEUs compared to controls following long-term in vitro
stimulation, which remained significant after controlling for a number of maternal
confounders including hookworm infection and maternal immunisation [40]. This
suggests that even after a full course of vaccinations, significant defects in Th1
and Th2-mediated immunity to Tetanus exist in the HEU. A limitation to the
aforementioned study, was the cross-sectional study design, where only one-year old
infants were studied. For T cell cytokines measured by intracellular cytokine staining
by flow cytometery after short-term Tetanus Toxoid stimulation, no differences in
IFN-γ, IL-2 or TNF-α were seen for a similar Ugandan cohort between 3 and 12
months of age, even when accounting for the ART-use and CD4 counts [127]. To
summarise, it appears there is no evidence that T cell function to Tetanus antigen is
perturbed in the HEU, however the effector function of other immune cells maybe
reduced as shown in culture assays. To date, only one study has directly compared
HEU and controls for cellular responses to Bordetella pertussis (BP) antigens, finding
lower frequencies of proliferating polyfunctional T cells in the HEU group [128].
Cellular responses to polyclonal and cytokine stimuli
As a measure of general immune competence by T cells, in vitro studies have used
anti-CD3 in conjunction with anti-CD28 monoclonal antibodies to trigger the T cell
receptor (TCR) and begin an intra-cellular signalling cascade that induces functional
responses, by-passing classical antigen presentation [141]. Maternal viral load and
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ART treatment during pregnancy have been shown to correlate anti-CD3-meditated
function in the HIV exposed neonate [142, 143]. Stimulation with anti-CD3 resulted
in reduced pro-inflammatory cytokines and increased regulatory cytokines in babies
born to mothers with uncontrolled HIV replication compared to those born to women
with undetectable viral loads in a Brazilian study [142]. These results were supported
by another observational study where detectable viremia during pregnancy (defined as
>80 copies/mL) was associated significantly elevated levels of IL-10, but lower levels
of TNF-α and IFN-γ in culture supernatants from neonatal anti-CD3 stimulated
cells compared to cells from mothers with undetectable viral loads during pregnancy
[143]. Another study which evaluated the upregulation of chemokine receptors on
mononuclear cells derived from cord blood in response to anti-CD3 stimulation found
no differences between HEU and HU groups however, exposure to GM-CSF in cell
culture preferentially upregulated CCR8 in HEU neonates [144].
1.2.5 Gene expression in HIV-exposed individuals
Gene transcription data from HEU infants have been lacking, and such studies
may give a broader insight into potential immune dysregulation in this population.
The most common genetic studies in HEU have measured mitochondrial DNA
content—a proxy for mitochondrial function—with conflicting results [146, 147,
81, 148, 149, 150] but suggest altered mitochondrial function as a result of direct
ARV-exposure [151, 152, 153]. In adult cohorts of known repeated exposures to
HIV without infection, ’HIV resistance’ is associated with a downregulation of genes
and pathways related to energy metabolism, NK cytotoxicity and T cell receptor
signalling [154]. The interpretation here is that resistance to infection is a result of
a downregulation of genes that HIV needs for successful infection. For babies who
are HIV exposed in utero, different physiological determinants are at play which
may result in gene expression patterns that are distinct from the HIV-exposed adult.






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































induce mitchondrial toxicity and damage with release of mitchondrial DNA [155, 156].
Vivanti et. al, [157] compared gene expression profiles between neonates exposed
to azidovudine or tenofovir-based combination therapies in utero from unexposed
controls (n=8, 9, and 8, respectively) by microarray analysis of isolated CD3 cells
isolated from cord blood. They found significant downregulation in the transcription
of genes related to DNA repair and telomere maintenance. The gene expression
profiles of CD34+ hematopoetic stem cells from 7 azidovudine-exposed and 6 control
newborns and found more than 300 differentially expressed genes in the exposed
group [158]. A recent study of Kenyan infants compared gene profiles in peripheral
blood mononuclear cells (PBMCs) in 12 month and 24 month-old HEU infants and
age-matched HU controls [159]. Almost two-thirds of differentially upregulated genes
in HEUs were related to plasma membrane receptor proteins found on immune cells
and some of these altered genes are associated with activation or the regulation
of inflammation, suggesting a dysregulation in the immune activation pathway.
Importantly, genes related to neutrophil function were repressed in HEUs, indicating
a potential defect of the innate immune system that may predispose these infants to
bacterial infections [159]. In this PhD, we propose to examine gene expression in
HEU birth blood, the sample closest to in utero HIV/ARV exposure and a time point
that mitigates confounders related to environmental and other post-natal exposures.
1.3 ARV regimens in HIV-exposed and uninfected neonates
The World Health Organisation (WHO) has specified which antiretroviral drug
regimens should be used during pregnancy, irrespective of clinical or immune status,
with disoproxil fumarate (TDF) making up the backbone of recommended regimens for
maternal health benefits, prevention of mother-to-child HIV transmission (TDF plus
emtricitabine: FTC & efavirenz: EFV) and prevention of HIV infection in uninfected
women (TDF-FTC, Truvada R©) [160]. These recommendations are extrapolated from
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limited clinical safety data. The scale-up of WHO’s recommended triple therapy
(Option B+) to pregnant and breastfeeding women living with HIV regardless of
maternal immune status has significantly reduced paediatric HIV infections [161].
As a result of these interventions, more foetuses and infants are exposed not only to
intrauterine HIV, but also intrauterine ARV, neonatal ARV prophylaxis, and in some
cases, to maternal HIV/ARVs via breastmilk [162]. These exposures comprise both
an infectious and drug exposure, making it often difficult to disentangle the effects
between the two. HIV/ARV exposure during pregnancy may lead to mitochondrial
toxicity [81, 163, 153], decreased postnatal growth [86], and genotoxicity [158, 157],
all of which could perturb energy metabolism and impact the short and long-term
metabolic health of cHEU.
1.4 Infant vaccination
As many as 1.5 million infant deaths yearly are attributed to vaccine preventable
diseases [164]. Vaccination remains the most cost-effective public health intervention
available for reducing childhood morbidity and mortality [165, 166, 167, 168]. Many
national vaccination programmes exist, the majority following recommendations by
WHO’s Expanded Programme on Immunisation (EPI) in their national immunisation
programmes [169, 170]. The following section will review broadly some of the vaccines
in the EPI currently in use in Sub-Saharan Africa, with a focus on the immune
responses generated by the vaccines and known correlates of protection.
1.4.1 Expanded Programme on Immunisation (EPI)
The World Health Assembly initiated the EPI in 1974 with the aim of increasing
vaccine coverage to all children globally to reduce infectious disease burden and mor-
tality in early life [171]. Vaccines against Tuberculosis (BCG), Diphtheria, Tetanus,
Pertussis, Measles and Poliomyelitis were part of the initial recommendation but this
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has since expanded to include yellow fever, Hepatitis B (HBV) and Haemophilus
influenzae type b in countries endemic to these diseases [170, 172]. Since the intro-
duction of the EPI, infant death under two years of age has decreased by 50% on
average in Sub-Saharan Africa [173]. WHO-UNICEF estimates for coverage in South
Africa between 2010-2018 are as follows: BCG (84%, 98% in the Western Cape),
DTP 1st dose (90%), DTP 3rd dose (87%), Measles 1st dose (MCV1: 89%) [174].
For Nigeria, the estimates for vaccine coverage are lower than national reports [169]
with WHO-UNICEF estimates for the same period as follows: BCG (55%), DTP 1st
dose (58%), DTP 3rd dose (49%), Measles 1st dose (MCV1: 66%) [174]. Clinical
and policy research output for childhood vaccines in South Africa and Nigeria are
the highest on the continent [175], and these two sites are a feature and focus of this
PhD thesis.
BCG
Tuberculosis is caused by Mycobacterium tuberculosis (Mtb) and is the leading
cause of death by a single etiological agent, with 1.5 million deaths and 10 million
developing active disease annually [173]. BCG is currently the only licensed vaccine
against TB and is effective against severe forms of disseminated Mtb infection in
children but has variable efficacy against the most common form of the disease,
adult pulmonary TB [176]. The uncertainty surrounding vaccine efficacy means
that national vaccination strategies differ, with many offering different doses, routes
of administration, timing of vaccination, and sub-strains of BCG [177]. Current
practices in South Africa and Nigeria are single intradermal dose at birth or shortly
thereafter as per WHO guidelines even in newborns whose HIV status is not confirmed
at delivery [178, 179]. BCG is contraindicated for symptomatic HIV-infected infants
due to the risk of BCG adverse events and disseminated BCG [180]. In high TB
endemic settings, the benefits of early BCG vaccination outweigh the risks associated
with delaying BCG until HIV status is known, especially when PMTCT programmes
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are in place [178].
While some studies demonstrate that BCG induces antibodies against mycobacte-
rial antigens [181, 182, 183, 184], their association with protective function is poor in
animal and human studies [185, 137]. BCG induces a complex cell mediated immune
response including Th1, Th2 and Th17 cytokines [186, 17, 187, 36]. Variability in
responses to BCG are in part related to geography as observed when comparing
infant responses in the tropics vs. further away from the equator. A study comparing
BCG vaccinated UK and Malawian infants, highlighted major differences in the
cytokine profiles induced by in vitro PPD stimulation [36]. At 3 and 12 months post
vaccination higher Th1 cytokines (IFN-γ, IL-2 and TNF-α) were observed in the
supernatants of PBMC-stimulated cultures from UK infants compared to Malawian
infants. In contrast Malawian infants had higher Th2 (IL-13, IL-5, IL-9 and IL-4) and
pro-inflammatory cytokines compared to UK infants. These differences highlight how
potential variations in environmental antigen priming, maternal factors and possible
exposure to infectious agents impact BCG immunogenicity [32, 188, 40, 126, 189].
For example helminth infections are more common in the tropics and these infections
may dampen immune responses [190, 191, 40] and treating helminth infection in
BCG vaccinated infants rescues pro-inflammatory responses while limiting regulatory
responses [32].
The route of immunisation appears to impact on the strength of immune re-
sponses [192]. A study comparing percutaneous and intradermal vaccination of
infants receiving BCG-Japan strain showed greater Th1 (IFN-γ, IL-2 and TNF-α)
and lower Th2 (IL-4) compared to intradermal vaccination with the same strain [192].
There is no evidence that the route of administration (percutaneous vs. intrader-
mal) impacts vaccine efficacy [193]. Delaying BCG vaccination does not impact
proliferative (Ki67+) Th1 responses [194] but has shown to increase the total CD4
memory Th1 response [187]. South African infants receiving BCG at birth had
lower polyfunctional (cells 3 or more cytokines) at one year compared to infants
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vaccinated at 10 weeks [187]. Polyfunctional CD4 responses are of interest in ra-
tional TB vaccine design studies as they correlate with delay or protection from
disease for some intra-cellular pathogens including HIV [136, 195, 137]. In mice,
BCG-induced polyfunctional responses in the lung have been shown to correlate
with reduced bacterial burden following aerosol Mtb challenge [135]. In humans,
while polyfunctional responses have correlated with in vitro mycobacterial growth
inhibition [196], these responses to not correlate with Mtb protection in vivo [187].
In a case-control study of South African infants who received BCG at birth found
no differences in polyfunctional CD4 cells at 10 weeks (IFN-γ, IL-2, TNF-α, IL-17)
between infants who were protected from TB disease to those who went on to develop
TB disease [187]. Polyfunctional cells induced by vaccination may not be sufficient
alone to protect against TB disease but remain targets for vaccine-induced immunity
in many novel TB vaccine candidates [197].
Diphtheria-Tetanus-Pertussis
Diphtheria is caused by toxogenic bacilli of the species Corynebacterium diphtheriae,
whose toxins affect multiple mucous membranes including the nasal airways and
skin [198]. It is spread through air droplets via coughing and complications brought
on by the toxin can lead to death. The most vulnerable are infants where case-
fatality rates can be as high as 20% [198]. EPI has had significant impact in
reducing the global incidence of Diphtheria and rates have fallen drastically from
close to 100 000 cases in 1980, to just over 7000 cases in 2016 [199]. In South
Africa and Nigeria between 2010 and 2018 there were 23 cases and 1870 cases,
respectively [199]. Tetanus is caused by the bacterium Clostridium tetani, and its
exotoxin Tetanospasmin is a potent neurotoxin whose clinical manifestations include
include lock-jaw, stiffness of the neck and difficulty swallowing [198] with eventual
respiratory failure. Low doses of the toxin, which enter via open wound can be fatal.
Neonatal Tetanus cases were low in South Africa between 2010 and 2018; with 8 cases
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reported, and none reported in 2018, whereas 1334 cases in Nigeria are reported in
the same year [200]. Pertussis (commonly known as whooping cough) is a contagious
respiratory tract infection caused by the bacterium Bordetella pertussis. Bacterial
products include pertussis toxin (PT), tracheal cytotoxin, filamentous hemagglutinin
(FHA), and pertactin which are antigenic [201] and result in disease. Estimates of
Pertussis incidences vary significantly due to the lack of reliable surveillance data
and infrastructure for reliable diagnostics [202, 203]. Africa nevertheless represents
the largest proportion of Pertussis cases and death in infants younger than 5 [204].
The re-emergence of Pertussis cases in lower income countries underscores the need
for accurate surveillance and improved vaccination coverage [202], particularly for
HEU infants as they benefit less from maternal antibody transfer during the neonatal
period [123].
Both cellular and antibody responses are induced by DTP. Passive immunity from
mothers is usually lower in HEU infants compared to HU infants, however protective
antibody titres are observed following 3 doses of DTaP [123]. Antibody levels to DTP
wane during childhood, and often booster vaccinations are required in adolescents or
adults [205]. Cell mediated responses to TT and BP include Th1 and Th2 cytokines,
with IFN-γ responses peaking at 6 months of age and waning thereafter [206]. Th2
responses, specifically IL-13 and IL-5 also peak at 6 months of age but are sustained
up to 18 months of age in infants who receive 3 doses [206]. Current practices for
vaccination against the aforementioned diseases are Diphtheria-Tetanus-Pertussis
(DTP) multi-component vaccines such as DTaP-IPV/Hib which includes inactivated
polio, Haemophilus influenzae type b and Hepatitis B antigens. This vaccine is
typically delayed until 6 weeks in infants as a number of factors impact immunity to
this vaccine: firstly maternal antibodies may interfere dampen responses to other
components of the vaccine [207, 208, 209] and secondly the Th2 bias of the early infant
immune system may affect responses to vaccination [210]. Studies in mice showed
that both adoptively transferred CD4 cells specific for FHA and passively transferred
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BP-specific sera were equally protective to aerosol BP challenge, suggesting both
Th1 and antibody-mediated roles in protecting against Pertussis infection [211].
Interestingly, CD4 cells expressing IFN-γ and IL-2 are able to mediate protection in
the absence of a detectable serum antibody response [211]. There has been a shift
from the use of whole-cell form of the Pertussis component (wP) of DTP to acellular
form (aP) due to adverse local reactions caused by the former [212]. Whole-cell
Pertussis induces a predominantly Th1 response [213] and long term protection in
mice is correlated with a sustained Th1 profile when antibodies have waned [214].
In children, aP induces a Th1/Th2 mixed response [215, 216] with antibody titres
waning quicker than wP [217].
1.5 Thesis aims
The over-arching aim of this thesis was to identify immune signals that differentiate
children who are exposed to ART/HIV-exposed yet uninfected from those who are
un-exposed. Infant whole blood samples were obtained from an existing multi-centre
study (Innate, Adaptive and Mucosal Immune Responses in Infants/INFANT study:
HREC 285/2012) that seeks to identify biological processes associated with protection
of mother-to-child transmission of HIV. Bio-banked samples were available for two
birth cohorts from Nigeria and South Africa infants sampled between birth and 9
months of age. This period coincides with both the administration of the majority of
EPI vaccines and reported infectious morbidity in the HEU [218, 88]. We explored
the hypotheses that HEU have altered T cell immunity compared to HU controls and
distinct gene profiles at birth. These hypotheses were tested in three distinct aims:
1. To identify differentially expressed genes (DEG) at baseline that delineate
cHEU from cHU.
2. To compare the ontogeny of T cell immunity between cHEU and cHU during
the first 9 months of life.
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3. To characterise how differences in the immunising strains of BCG, the first
vaccine received in these infants, impacts T cell immunity to both mycobacterial
and non-mycobacterial antigens in cHEU and cHU.
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Chapter 2
Transcriptome of HEU newborns
2.1 Introduction
Rationale for measuring gene expression in the HEU
Gene transcription data from HEUs are lacking, and such studies may give a broader
insight into potential pathways involved in immune dysregulation in this population.
Because the transcriptome measures all actively transcribed genes in a sample in
an unbiased manner, much the underlying biology from a sample can be captured
in a single experiment without an a priori selection of which biological signals may
differ between two groups of interest. In a recent study of 1 - 2 year-old Kenyan
infants, a total of 262 differentially expressed genes between HEU and HU controls
[159]. Among the differentially down-regulated genes were those related to neutrophil
function in HEUs, suggesting a vulnerability of the innate immune system [159].
The infants in the Kenyan study were between 1 and 2 years of age, therefore
postnatal exposures to environmental antigens are potential confounding variables
in interpreting the data. Characterising the transcriptome in samples closest to in
utero time point would better reflect transplacental exposures to virus, ART or the
maternal cytokine milieu on the biology of the newborn immune system [219, 220,
144, 129, 149, 118, 221, 222, 113]. To this end, we characterised mRNA transcripts
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in birth whole bood of HEU and HU newborns. An added advantage of using whole
blood rather than PBMCs, was that more of the immune landscape could be covered
as additional cellular subsets such as eosinophils and neutrophils are present in whole
blood. Furthermore, this sample closely mimics in vivo physiological conditions.
All infants were confirmed HIV negative by PCR at birth, and all HIV+ mothers
received antiretroviral treatment during pregnancy as per national guidelines [223,
224].
2.2 Methods
2.2.1 RNA-Seq library construction and sequencing
A volume of 500µL of venous whole blood at birth was collected and aliquoted into
PAXgene R© fluid at the ratios recommended by the manufacturer (BD). Aliquots
of whole blood in PAXgene R© fluid were kept at room temperature for 24 hours
before storing at -80◦C as per manufacturer instructions. RNA was purified using
the PAXgene Blood RNA Kit (Qiagen), and RNA concentration and quality was
assessed using a NanoDrop and an Agilent Bioanalyzer, respectively. Alpha and beta
globin mRNA was depleted from 1µg of RNA using the ThermoFisher GLOBINclear-
Human Kit. Ten nanograms of globin-depleted RNA was used as input for cDNA
synthesis using the Clontech SMART-Seq v4 Ultra Low Input RNA kit according to
the manufacturer’s instructions. Amplified cDNA was fragmented and appended with
dual-indexed bar codes using the Illumina NexteraXT DNA Library Preparation kit.
Libraries were validated by capillary electrophoresis on an Agilent 4200 TapeStation,
pooled, and sequenced on an Illumina HiSeq3000 at 100SR at an average read depth
of 15 million reads per sample. FASTQ files from the sequencer were aligned to the
Ensembl reference genome using the STAR read aligner [225].
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2.2.2 Differential gene analysis
We used the DESeq2 package to identify differentially expressed genes between groups.
Briefly, the DESeq2 pipeline uses the high dimensional row count matrix from the
sequencing reads it’s data input. Quality control steps include normalisation of the
read counts to account for systematic effects that are not related to biology [226].
DESeq2 models the raw counts for each gene using a negative binomial model, to
estimate priors for log fold change and dispersion, and to calculate posterior estimates
for these quantities. Variance stabilisation transformation from the fitted dispersion
mean relations was applied using the regularised log (rlog) method in DESeq2 to
normalise raw counts. We included cohort site and gender as co-variables in the
DESeq2 model design to account for these effects on HIV exposure. Differentially
expressed genes were considered based on based on FDR<0.05 and an absolute fold
change (FC)>1.0 normalised counts.
2.2.3 Gene-set enrichment analysis
Gene set enrichment analysis was performed using the GSEA software version 3.0
[227]. Log transformed counts, generated using the rlog method from the DESeq2
package, were used as input for the GSEA analyses. Gene sets representing the
activity of pathways were derived from the C2, C5 and Hallmark collections of the
Molecular signature database (MSigDB)[228]. For all GSEA analyses, phenotype
permutation was used. Gene-sets/modules were considered significantly up- or down
regulated based on normalised effect sizes >1.5 between phenotype groups with an




Paxgene samples were selected for sequencing based on RNA quality with RNA
integrity values >7.5 (Appendix 7.3). It is unclear why Jos samples had poorer
RIN scores compared to CT samples despite showing comparable RNA yields. A
likely explanation may be related to fluctuations in shipping temperatures, thus
only a total of 11 samples from Jos were included. All HIV+ women were on fixed
dose combination antiretroviral treatment (efavirenz, emtricitabine and tenofovir
disoproxil fumarate) during pregnancy. Clinical characteristics between cHEU and
cHU control groups were similar except for the distribution of gender in the Jos
cohort. To test the hypothesis that specific genes were up- or down-regulated in
cHEU, the transcriptome of birth whole blood was analyzed in 61 samples using RNA
Seq analyses (Table 2.1). To account for potential cohort and gender confounders,
we included cohort and gender as covariates in our DESeq2 model design.
Table 2.1: Baseline characteristics for RNA Seq analyses
CT P-value Jos P-value
HEU (n=33) HU (n=17) HEU (n=6) HU (n=5)
Gestational age (weeks) 39 [38-40] 39 [38-39] 0.22 39 [38-40] 40 [40-41] 0.18
Birth weight (g) 3270 [2880-3440] 2940 [2900-3230] 0.12 2825 [2538-3000] 3500 [3400-3600] 0.15
Length (cm) 48 [45-50] 49 [47-50] 0.68 45.5 [45-46.8] 50 [48-52] 0.14
n (Male/Female) 10/23 6/11 0.72 1/5 5/0 0.006
Numbers indicate median and (IQR) unless otherwise stated. P-values calculated using Wilcoxon Rank Sum test.
Chi-squared test of homogeneity was used to compared distribution of infant genders between exposure groups.
2.3.2 Differential gene analysis identifies a minor set of upregulated
genes in HEUs
We first performed a principal component analysis (PCA) on all 61 samples comprising
HEU and HU infants from both cohorts. PCA did not cluster by HIV exposure, or
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by cohort site (Figure 2.1), suggesting no distinct overall variation in genes between









































Figure 2.1: Principal component analysis of transcriptome data shows no clustering by
HIV exposure status or cohort site. PCA plots are colour coded by HIV exposure (A) or
Cohort site (B). HU = HIV-unexposed, HEU = HIV exposed and uninfected, CT = Cape
Town
.
After DESeq2 modelling, we filtered differentially expressed genes (DEGs) based
on FDR<0.05 and an absolute fold change (FC) >1.0 for normalised counts. This
resulted in a list of 15 DEGs, 3 of which were upregulated in HEUs, and 12 that
were downregulated. Of the down-regulated genes 8/12 were Y-linked genes. Of
the upregulated genes, 2 were homologues of the alpha arrestin family ARRDC4
(FC relative to HU: 2.3, p-adj<0.0001) and TXNIP (FC relative to HU: 1.4, p-






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Significance ● ●Not significant padj<0.05 & abs(FC) > 1.5
Volcanoplot DESeq2
Figure 2.2: Volcano plot of differentially expressed genes between HEU and HU groups
at birth. Significant differential expressed genes (DEG) are shown in red and gene names
are labelled, and non significant genes are shown in black. Threshold for DEG relative to
HU controls were set at >1.0 absolute fold change (abs FC) and p-adjusted <0.05 and are












Figure 2.3: Three genes are increased in HEUs at birth. Heatmap shows the three genes
with >1.0 fold increase in normalised counts relative to HEU and p-adjusted <0.05. Relative
expression is based on z-scores of rlog transformed counts.
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2.3.3 No distinct pathways are altered in HEUs
To complement differential expressed gene analyses, we applied gene-set enrichment
analyses to identify whether the groups/modules of genes representing distinct bio-
logical pathways were enriched/downregulated in the HEU infant at birth. As shown
in Tables 2.3 (C5: ontology genesets), 2.4 (C2: curated genesets) and 2.5 (Hallmark
gene sets), no gene sets passed an FDR cut-off of less than 0.05. Importantly, while
differential gene analyses found two genes involved in the glycolysis and/or ROS
generation [229], none of the gene modules associated with glycolysis, reactive-oxygen
species or oxidative phosphorylation pathways showed any significant differences
between HEU and HU infants.
2.4 Discussion
We used RNA-sequencing technology as it has a number of advantages over microarray
including wider dynamic range [230] and greater sensitivity and specificity [231, 232,
233]. We elected to use whole blood rather than isolated cell populations which
provides a global snapshot of actively transcribed genes in HEU. Differential gene
analysis revealed that TXNIP (Thioredoxin Interacting protein), ARRDC4 (Arrestin
domain containing 4) and KLF10 (Kruppel-like factor 10) were over-expressed in
the whole blood of HEU newborns compared to HU controls. Gene-set enrichment
analyses however could not discriminate HEU from HU meaning that the small
number of differentially expressed genes did not translate to differences in distinct
biological pathways. We acknowledge the following caveats: (i) gene expression
measurements on whole blood rather than pure cell populations mean that any small
changes in gene modules/pathways are likely drowned out by the inherent noise of a
mixed cell population, (ii) the sample size used in this study may have been limiting
factor in detecting enriched gene modules directly ex vivo (iii) functional immune






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2.5: Results of gene-set enrichment analysis for Hallmark database comparing HEU
and HU groups at birth
NAME NES NOM p-val FDR q-val
IL6_JAK_STAT3_SIGNALING 1.19 0.19 1
IL2_STAT5_SIGNALING 1.16 0.14 1
TGF_BETA_SIGNALING 1.15 0.23 1
G2M_CHECKPOINT 1.12 0.34 1
E2F_TARGETS 1.09 0.38 1
MTORC1_SIGNALING 1.06 0.40 1
GLYCOLYSIS 1.05 0.36 1
HEDGEHOG_SIGNALING 1.02 0.44 1
HYPOXIA 0.99 0.47 1
Normalised effect size (NES) are shown in descending order for top 10 gene modules
with nominal p-values (NOM p-val). FDR q-values <0.05 were considered significant.
in ARRDC4 and TXNIP mRNA in this heterogenous mixed cell samples are worth
investigating further. Our finding that no significant gene pathways are altered in
newborns from mothers on suppresive ART suggest that both biological and immune
signals are indistinguishable from healthy un-exposed controls. We do not discount
that age-related transcriptional differences in the HEU may become apparent later
in life. A recent study of Kenyan HEU infants sampled at 12-month and 24 months
found 188 upregulated and 74 down-regulated genes in the HEU [159]. Despite a
relatively small sample size (19 HEU vs. 15 HU), these differentially expressed genes
translated to significantly enriched immune gene pathways in the HEU. Among the
downregulated genes in HEUs was the alpha arrestin ARRDC3 (log2foldchange =
-1.5, p-adj<0.0001), which contradicted our finding of an upregulation in ARRDC4
(log2foldchange = 4.9, p-adj<0.0001)—a related alpha arrestin [234]. Alpha arrestins
together with TXNIP regulators of glucose metabolism, playing key roles in glucose
production in the liver and uptake from peripheral tissues [235, 236]. None of
the functional enrichment terms found by Musimbi and colleagues translated to
alterations in metabolic pathwways [159]. Differences in environmental exposures
between HEU and age-matched HU controls may have confounded the interpretation
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in the aforementioned study. For this study, we chose the birth time-point as being
representative of direct in utero HIV/ART exposure. It is unclear what proportion of
mothers were on antiretroviral treatment in the Kenyan study however, the authors
did report that all infants received post exposure prophylaxis. We therefore report
that in the context of suppressive ART during pregnancy, HEU newborns do not
have significant alterations in gene transcripts in whole blood.
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Chapter 3
T cell marker expression in HEU
infants—activation, proliferation,
regulation and markers of HIV
susceptibility
3.1 Introduction
Rationale for measuring immune activation markers in the HEU
The over-arching hypothesis for this section is that maternal HIV infection increases
markers of T cell activation and proliferation ex vivo in exposed infants. Furthermore,
we hypothesise that over time, these differences in these markers between HEUs and
HU infants become less apparent due to reduced HIV/ART exposure. The rationale
for these hypotheses comes from two major observations: (i) maternal HIV infection
is associated with increased soluble markers of inflammation both systemically and
in the placenta [237] and (ii) patterns in the expression of plasma cytokines in HIV-
infected mothers are mirrored in cord blood plasma of their uninfected newborns
[142] suggesting a shared inflammatory milieu. This hyper-inflammatory environment
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may not only activate immune subsets in the neonate [144], but also result in a
compensatory regulatory response as seen in HEUs who express elevated levels of
regulattory T cell markers [140]. In this PhD, the focus was on markers defining
activated T cells, where upregulation of HLA-DR and Ki67 have been shown to be
useful surrogates for disease state, disease susceptibility, antigen load and response
to treatment [238, 239, 240, 241]. A flow cytometry panel was designed to define
the following peripheral blood T cell populations: (i) activated cells defined by
HLA-DR expression (alone or combination with proliferation marker Ki67), CD25
co-expressing CD127hi (from hereon referred to as CD25+ cells) or PD-1 expressing
T cells; (ii) "regulatory-like T cells" defined by CD4 co-expressing CD25 and CD127lo
(from hereon reffered to as "Treg-like"; (iii) HIV target cells defined by CD4 T cells
co-expressing CCR5hi and gut-homing marker α4β7hi. The inclusion of the integrin
α4β7 and the chemokine receptor CCR5 allowed the co-expression of activated
gut-homing T cells which may also be potential targets for HIV infection [242, 243,
244, 245] and may predict HIV acquisition [245]. A major advantage of this study
was that longitudinal sampling allowed us to model differences over time. Specifically,
we tested three hypotheses with respect to HIV/ART exposure (in utero and/or
postnatally via breastfeeding): (i) HEU infants have greater frequencies of markers
of activation at birth compared to HU controls, and that these differences would
decrease over-time; (ii) HEU infants have elevated frequencies of regulatory-like T
cells compared to HU controls and (iii) HEU infants would have increased frequencies
of HIV target cells compared to HU controls.
3.2 Methods
3.2.1 Whole blood fixation
For T cell activation measurements, whole blood was fixed with BD FACSTMlysing
solution directly ex vivo and within 6 hours of blood draw. Briefly, blood was drawn
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into sodium heparin tubes and 500 µL of the anticoagulated blood was fixed before
cryo-preservation in 10% DMSO and 90% FCS before storing in LN2. For Jos samples,
cells were cryo-preserved in 10% DMSO and 90% FCS, stored at -70◦C and shipped
within 6 months to the University of Cape Town (UCT) and then transferred to LN2.
Analysis of all samples was performed at the core laboratory at the UCT.
3.2.2 Cell staining, antibodies and flow cytometry
Batched stored samples were thawed quickly at 37◦C and washed twice with 1X BD
PermWash buffer then incubated in 1X BD PermWash for 10 minutes. The antibody
cocktail mix diluted in 2% FCS in PBS was added and incubated at 4◦C for 45 minutes.
Cells were washed twice with in 2% FCS in PBS and re-suspended in 0.3 mL PBS
for cell acquisition using a Beckton Dickinson LSRII flow cytometer (SORF model).
The following monoclonal antibody-fluorochrome conjugates were used in the T cell
activation/proliferation panel: α4β7-R-phycoerythrin (PE), CD8-V500, CD3-Alexa
Fluor-700, CCR5-PE-Cy7, Ki67-Fluorescein isothiocyanate (FITC; BD), CD27 PE-
Cy5, HLA-DR- Allophycocyanin-Cy7 (APC-Cy7), CD45-BV650 (Biolegend), CD4
PE-Cy5.5 (Invitrogen), CD127 PE-Texas Red-X (Beckman Coulter). A minimum
of 50 000 CD3 events were collected on FACS DIVA v6 software. Post-acquisition
compensation and analysis was performed in FlowJo version 9 (FlowJo, LLC). Figure
3.1 shows the gating strategy employed for ex vivo T cell marker quantification.
Specific combinations of these markers identified subsets of interest: CD127 was used
to define CD127lo and CD127hi subsets, which when co-expressing CD25, allowed
us to discriminate T cells with Treg-like surface phenotype or CD25+ activated cells
respectively [246, 247]. The co-expression of gut-homing marker α4β7+ and CCR5hi
on CD4 cells were used as a proxy for HIV susceptibility or potential HIV target cells
[242, 248, 243, 244, 245]. Other T cell subsets defined included activated (HLA-DR
or PD-1) and/or proliferating (Ki67) cells.
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3.2.3 Statistical analyses
Statistical analyses of flow cytometry data was performed in R [249]. Non-parametric
comparisons between independent groups was performed using Wilcoxon Rank Sum
test (Mann Whitney U test). For longitudinal data, a repeated measures analysis
of variance (ANOVA) was used to assess the effect of time, HIV exposure or the
interaction of these variables on the expression of T cell markers measured. A
Friedman’s test with the Wilcoxon-Nemenyi-McDonald-Thompson post-hoc test
[250] was used to determine which time intervals were significantly different in the
frequencies of markers measured.





























































































































Figure 3.1: Flow cytometry gating strategy to define T cell markers. All markers were
gated on parent CD4 and CD8 populations after gating on singlets, lymphocytes, time
gates (to exclude acquisition artefacts) and CD3+ subsets. Activated and regulatory
(Treg-like) subsets were defined based on the co-expression of CD25 with CD127hi or
CD127lo expression respectively. In addition PD-1 expression was a proxy for activated
cells. CCR5 was gated on brightest CCR5+ population (CCR5hi). Total HLA-DR and
total Ki67 were gated on CD4 and CD8 cells. Potential HIV target cells were defined on the
CD4 parent population co-expressing CCR5hi and the brightest α4β7 population (α4β7hi)
[248]. Fluoresence minus one controls were run to establish optimal gates (Appendix 7.1).
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Table 3.1: T cell markers measured ex vivo between HEU and HU infants
Marker Function Rationale for inclusion References
CCR5 Adhesion and homing Co-receptor for HIV viral entry [244]
HLA-DR Antigen presentation Identifies activated T cells [251]
CD25 IL-2 signalling Identifies activated/regulatory T cells [246]
Ki67 Nuclear protein Identifies actively dividing T cells [252]
CD127 IL-7 signalling Down-regulated by regulatory T cells [247]
α4β7 Adhesion/gut homing Identifies potential HIV target cells [244, 245]
3.3 Results
3.3.1 CD25 expression by CD8 T cells in HEUs is significantly in-
creased at 36 weeks of life
A number of T cell markers (Table 3.1) were measured directly ex vivo and the
frequency of expression was first compared between HEU and HU controls at each
individual time point (Figures 3.3 and 3.4 & Table 3.4). This analysis was restricted
to CT infants as the number of cHU controls available in the Jos cohort were
insufficient for a comparison by HIV exposure groups (Appendix 7.2). Overall, no
differences were seen in CD4 cells expressing the markers α4β7, CCR5hi, HLA-DR
or Ki67 between HEU and HU controls at any time-point. For CD8 cells, there
were trends towards higher expression of the activation marker HLA-DR in the
HEU group compared to controls at week 0 (medians 0.12 vs. 0.01 respectively,
p=0.05), week 7 (medians 0.84 vs. 0.01 respectively, p=0.01) and week 36 (medians
0.81 vs. 0.17 respectively, p=0.003), though these differences did not hold after
multiple comparison correction. Of note, was the increased frequency CD8 cells
expressing activation marker CD25 among HEUs compared to controls at week 7
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(medians 0.31 vs. 0.04 respectively, p=0.01), and at week 36 (medians 0.52 vs. 0.03
respectively, p<0.001). Potential HIV target cells (CD4+CCR5hi+α4β7+) and T
cells with a regulatory-like surface phenotype (CD4+CD25+CD127lo: ’Treg-like’)
were comparable between HIV exposure groups at all the time points measured in
this study (Table 3.4). In summary, differences in activated phenotypes between HIV






































































































































































































Figure 3.2: Comparison of CD4 markers of activation, proliferation and gut homing be-
tween HE and HU controls. T cell markers (vertical strip text) that were measured
ex vivo are compared between HIV exposure groups: HEU (maroon circles, n=10) and
HU (grey circles, n=16) and are expressed as a percentage of the parent CD4 population.
Horizontal strip text indicate age (weeks after birth). CCR5hi+α4β7hi represents potential
HIV target cells, CD25 represents activated CD4 cells that co-expressed CD127hi and
Treg-like cells were CD25+CD127lo. An unpaired Wilcoxon Ranked Sum test was used
to compare expression between cHEU and cHU groups. P-values <0.001 were significant


































































































































































































Figure 3.3: Comparison of CD8 markers of activation, proliferation and gut homing be-
tween HEU and HU controls. T cell markers (vertical strip text) that were measured
ex vivo are compared between HIV exposure groups: HEU (maroon circles, n=10) and
HU (grey circles, n=16) and are expressed as a percentage of the parent CD8 population.
Horizontal strip text indicate age (weeks after birth). CCR5hi+α4β7hi represents potential
HIV target cells, CD25 represents activated CD8 cells that co-expressed CD127hi. An
unpaired Wilcoxon Ranked Sum test was used to compare expression between HEU and
HU groups. P-values <0.001 were significant after adjusting for multiple comparisons using
the Holm’s step-down method.
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Table 3.2: Frequencies of T cell markers ex vivo between HEU and HU control groups
Time T cell subset Marker HEU median (IQR) HU median (IQR) P-value P-adj
0 CD4 α4β7 0.16 (0.08-1.6) 0.21 (0.08-0.47) 0.78 1.00
CCR5hi 0.17 (0.06-0.67) 0.13 (0.08-0.49) 0.94 1.00
CD25 1.36 (0.98-2.78) 1.72 (0.96-2.41) 0.86 1.00
HLA-DR+Ki67+ 0.03 (0.01-0.09) 0.02 (0.01-0.06) 0.49 1.00
HLA-DR 0.02 (0.01-0.05) 0.02 (0.01-0.02) 0.64 1.00
Ki67 0.57 (0.3-2.45) 1.13 (0.59-2.29) 0.39 1.00
CCR5hiα4β7hi† 0.01 (0-0.06) 0 (0-0.01) 0.38 1.00
"Treg-like"‡ 3.58 (2.77-4.2) 3.67 (3.38-4.45) 0.44 1.00
PD-1 0.38 (0.22-0.66) 0.30 (0.26-0.80) 0.69 1.00
7 CD4 α4β7 1.28 (0.38-4.64) 1.09 (0.74-1.94) 0.93 1.00
CCR5hi 1.61 (1.42-2.43) 3.29 (1.68-4.03) 0.21 1.00
CD25 1.6 (0.9-2.39) 1.38 (0.82-2.01) 0.98 1.00
HLA-DR+Ki67+ 0.22 (0.07-0.48) 0.11 (0.08-0.22) 0.36 1.00
HLA-DR 0.06 (0.05-0.08) 0.05 (0.03-0.13) 0.64 1.00
Ki67 3.68 (2.31-4.03) 2.98 (2.64-4.03) 0.72 1.00
CCR5hiα4β7hi† 0.14 (0.04-0.23) 0.1 (0.07-0.18) 0.72 1.00
"Treg-like"‡ 5.03 (3.87-6.1) 5.35 (5.14-6.75) 0.19 1.00
PD-1 1.78 (1.11-2.42) 1.84 (1.23-2.41) 0.86 1.00
15 CD4 α4β7 1.47 (0.21-5.42) 0.68 (0.35-2.68) 0.98 1.00
CCR5hi 1.83 (1.6-2.49) 1.4 (0.93-2.37) 0.6 1.00
CD25 1.39 (0.94-1.86) 0.93 (0.64-2.74) 0.72 1.00
HLA-DR+Ki67+ 0.27 (0.18-0.32) 0.18 (0.12-0.23) 0.07 1.00
HLA-DR 0.07 (0.03-0.11) 0.07 (0.04-0.23) 0.93 1.00
Ki67 3.06 (1.74-3.66) 2.6 (2.27-3.32) 0.89 1.00
CCR5hiα4β7hi† 0.11 (0.04-0.29) 0.1 (0.05-0.2) 0.93 1.00
"Treg-like"‡ 4.72 (4.29-5.66) 5.9 (4.94-7.44) 0.13 1.00
PD-1 2.93 (2.56-4.64) 3.2 (2.60-3.54) 0.89 1.00
36 CD4 α4β7 1.37 (0.5-5.52) 2.22 (1.04-2.83) 0.98 1.00
CCR5hi 1.69 (1.06-2.41) 1.38 (0.99-2.78) 0.62 1.00
CD25 1.82 (1.23-2.31) 1.93 (0.67-3.14) 0.75 1.00
HLA-DR+Ki67+ 0.25 (0.13-0.28) 0.15 (0.09-0.3) 0.43 1.00
HLA-DR 0.07 (0.05-0.1) 0.08 (0.05-0.1) 0.84 1.00
Ki67 2.58 (1.75-3.57) 2.48 (1.56-3.14) 0.46 1.00
CCR5hiα4β7hi† 0.15 (0.04-0.3) 0.21 (0.11-0.42) 0.56 1.00
"Treg-like"‡ 5.54 (5.22-6.61) 5.81 (5.15-7.31) 0.29 1.00
PD-1 3.99 (2.80-5.32) 3.30 (1.84-5.02) 0.57 1.00
0 CD8 α4β7 0.2 (0.06-15.55) 0.91 (0.09-21.45) 0.41 1.00
CCR5hi 0.27 (0.02-2.67) 0.08 (0.03-0.14) 0.62 1.00
CD25 0.05 (0.01-0.46) 0.06 (0.02-0.11) 0.85 1.00
HLA-DR+Ki67+ 0.02 (0-0.73) 0.01 (0-0.03) 0.53 1.00
HLA-DR 0.12 (0.01-0.56) 0.01 (0.01-0.02) 0.05 1.00
Ki67 1.62 (0.6-4.1) 2.52 (1.28-3.34) 0.41 1.00
CCR5hiα4β7hi 0 (0-0.42) 0.02 (0-0.04) 0.4 1.00
PD-1 0.96 (0.45-2.94) 0.69 (0.50-1.59) 0.57 1.00
7 CD8 α4β7 10.27 (2.59-27.73) 1.32 (0.67-8.1) 0.17 1.00
CCR5hi 5.83 (3.86-6.25) 2.14 (1.39-3.43) 0.06 1.00
CD25 0.31 (0.2-0.39) 0.04 (0.03-0.09) 0.01 0.21
HLA-DR+Ki67+ 1.14 (0.09-3.89) 0.14 (0.1-1.28) 0.6 1.00
HLA-DR 0.84 (0.16-3.72) 0.07 (0.03-0.18) 0.01 0.34
Ki67 5.8 (0.62-6.97) 4.68 (2.64-7.15) 0.6 1.00
CCR5hiα4β7hi 1.69 (0.21-2.32) 0.25 (0.16-0.54) 0.16 1.00
PD-1 2.63 (1.03-5.06) 1.00 (0.85-2.59) 0.29 1.00
15 CD8 α4β7 4.01 (1.35-26.1) 1.8 (0.43-11.85) 0.49 1.00
CCR5hi 4.89 (2.06-11.58) 3.15 (1.18-4.81) 0.39 1.00
CD25 0.13 (0.07-0.38) 0.04 (0.01-0.08) 0.11 1.00
HLA-DR+Ki67+ 2.67 (1.22-5.1) 2.58 (0.19-3.55) 0.64 1.00
HLA-DR 0.67 (0.26-2.8) 0.29 (0.04-0.74) 0.1 1.00
Ki67 4.83 (1.08-8.29) 5.61 (2.38-13.45) 0.47 1.00
CCR5hiα4β7hi 0.64 (0.09-2.79) 0.26 (0.05-0.96) 0.49 1.00
PD-1 5.07 (3.34-11.24) 3.21 (1.58-6.42) 0.46 1.00
36 CD8 α4β7 6.43 (1.48-20.93) 3.27 (1.3-13.62) 0.66 1.00
CCR5hi 7.82 (3.35-11.73) 2.89 (1.6-5.61) 0.06 1.00
CD25 0.52 (0.07-1) 0.03 (0.01-0.05) <0.001 0.04
HLA-DR+Ki67+ 2.29 (0.17-5.08) 0.92 (0.33-1.53) 0.75 1.00
HLA-DR 0.81 (0.37-4.68) 0.17 (0.06-0.46) 0.003 0.10
Ki67 2.68 (0.55-7.99) 3.26 (2.84-3.66) 0.88 1.00
CCR5hiα4β7hi 0.75 (0.42-2.86) 0.42 (0.17-1.47) 0.25 1.00
PD-1 8.11 (3.82-10.90) 3.31 (2.07-5.58) 0.11 1.00
Comparison of frequencies of T cell markers between HEU (n=11) and HU (n=16) in CT infants. Median percentage
of parent population (CD4 or CD8) with (IQR) are shown for week 0–36 after birth. Wilcoxon Ranked Sum tests
was used to compare HEU and HU groups. P-adjusted values <0.05 were considered significant after multiple
comparison adjustment using Holm’s step down method. †HIV target cells were defined as CCR5hiα4β7hi+ on
CD4 cells.
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3.3.2 HEUs differ from HU controls in the expression of activated
CD8 T cells over the course of the first 36 weeks of life
We modelled the expression of these T cell markers in blood samples that were
matched from birth to 36 weeks. Initially within group differences over time were
analysed for each of the HIV exposure groups. As shown in Figure 3.2A, two CD4
subsets in particular followed similar kinetics in both HEU and HU groups—PD-1
and "Treg-like" CD4 cells which increased significantly from birth to week 36 (both
p<0.001). Next, we applied a repeated measures analysis of variance (ANOVA)
to account for correlated observations within subjects and to determine whether
age and HIV exposure impacted the expression of these markers (Tables 3.2 &
3.3). Irrespective of HIV exposure, age (time) impacted on the frequencies of all
CD4 markers measured except CD25 (p=0.80). When we stratified infants by
HIV exposure groups, to examine which time intervals that explained the overall
differences, we observed remarkable concordance between successive time points for
HEU and HU groups (Table 7.2). For CD8 cells (Table 3.4), we observed significant
overall differences (across all time points) by HIV exposure—in the expression of
CD25 (p<0.001), HLA-DR (p<0.001) and PD-1 (p<0.001). Age as a variable did not
have a significant interaction effect with HIV exposure group. Like CD4 cells, the
frequencies of these markers followed similar increases/decreases between successive
time points (Table 3.4).
The following conclusions were drawn from cross-sectional and longitudinal
analyses: (i) the frequencies of CD4 and CD8 T cells expressing markers of acti-
vation/proliferation/HIV target cells between HEU and HU infants follow similar
patterns of peaking and waning; (ii) CD8 T cells from HEUs are preferentially
activated compared to HU controls—expressing significantly higher frequencies of
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Figure 3.4: Kinetics of T cell markers by HIV exposure status. T cell markers (indicated
in horizontal strip text) that were measured ex vivo are plotted longitudinally in matched
samples. X-axes indicate the following time-points in weeks after birth: 1 (week 0), 2 (week
7), 3 (week 15), 4 (week 36). A local regression line (loess smoothing with 95% confidence
intervals: shaded area) was fitted to the data for visualisation purposes. HIV exposure
groups: HEU (maroon circles, n=10) and HU (grey circles, n=16) and are expressed as
a percentage of the parent T cell population: A (CD4) or B (CD8). CCR5hi+α4β7hi
represents potential HIV target cells, CD25 represents activated CD4 cells that co-expressed
CD127hi and ’Treg-like’ cells were CD25 cells co-expressing CD127lo. P-values shown are
the result of a Friedman’s test evaluating differences across all time-points, and p<0.001
were considered significant after multiple comparison adjustment.
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Table 3.3: Repeated measures analysis of variance table for CD4 T cell markers
Df Sum Sq Mean Sq F value Pr(>F) Marker
Age 3 7.69 2.56 5.83 0.001 α4β7
Group 1 1.20 1.20 2.73 0.10
Age:Group 3 0.21 0.07 0.16 0.92
Residuals 60 26.36 0.44
Age 3 12.08 4.03 29.00 <0.001 CCR5hi
Group 1 0.19 0.19 1.36 0.25
Age:Group 3 0.18 0.06 0.43 0.73
Residuals 60 8.34 0.14
Age 3 0.11 0.04 0.34 0.80 CD25
Group 1 0.19 0.19 1.86 0.18
Age:Group 3 0.09 0.03 0.29 0.83
Residuals 60 6.25 0.10
Age 3 16.51 5.50 14.65 <0.001 HLA-DR+Ki67+
Group 1 0.92 0.92 2.44 0.12
Age:Group 3 0.82 0.27 0.73 0.54
Residuals 60 22.54 0.38
Age 3 8.30 2.77 6.60 0.001 HLA-DR
Group 1 0.26 0.26 0.63 0.43
Age:Group 3 0.57 0.19 0.45 0.72
Residuals 60 25.13 0.42
Age 3 3.25 1.08 7.77 <0.001 Ki67
Group 1 0.05 0.05 0.37 0.55
Age:Group 3 0.54 0.18 1.29 0.29
Residuals 60 8.35 0.14
Age 3 37.09 12.36 23.55 <0.001 CCR5hi+α4β7+
Group 1 0.65 0.65 1.24 0.27
Age:Group 3 2.48 0.83 1.57 0.20
Residuals 60 31.50 0.52
Age 3 0.57 0.19 10.79 <0.001 ’Treg-like’
Group 1 0.01 0.01 0.61 0.44
Age:Group 3 0.02 0.01 0.30 0.82
Residuals 60 1.06 0.02
Age 3 6.54 2.18 23.77 <0.001 PD-1
Group 1 0.15 0.15 1.61 0.21
Age:Group 3 0.11 0.04 0.41 0.75
Residuals 60 5.50 0.09
Results of a repeated measures analysis of variance (ANOVA) to assess the effect of age (weeks 0–36) or HIV
exposure (Group), and the interaction between these two variables, on the frequency of expression of the listed T
cell markers by CD4 cells in CT infants. Pr<0.05 were considered significant.
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Table 3.4: Repeated measures analysis of variance table for CD8 T cell markers
Df Sum Sq Mean Sq F value Pr(>F) Marker
Age 3 9.27 3.09 2.19 0.10 α4β7
Group 1 0.88 0.88 0.62 0.43
Age:Group 3 2.63 0.88 0.62 0.60
Residuals 60 84.72 1.41
Age 3 27.85 9.28 7.10 <0.001 CCR5hi
Group 1 4.47 4.47 3.42 0.07
Age:Group 3 6.73 2.24 1.72 0.17
Residuals 60 78.41 1.31
Age 3 2.38 0.79 1.52 0.22 CD25
Group 1 8.39 8.39 16.12 <0.001
Age:Group 3 2.29 0.76 1.47 0.23
Residuals 60 31.21 0.52
Age 3 57.32 19.11 20.69 <0.001 HLA-DR+Ki67+
Group 1 0.34 0.34 0.37 0.55
Age:Group 3 3.01 1.00 1.09 0.36
Residuals 60 55.42 0.92
Age 3 16.07 5.36 6.91 <0.001 HLA-DR
Group 1 18.45 18.45 23.81 <0.001
Age:Group 3 0.49 0.16 0.21 0.89
Residuals 60 46.49 0.77
Age 3 1.57 0.52 1.55 0.21 Ki67
Group 1 2.68 2.68 7.95 0.01
Age:Group 3 0.78 0.26 0.77 0.52
Residuals 60 20.26 0.34
Age 3 55.90 18.63 13.89 <0.001 CCR5hi+α4β7+
Group 1 0.21 0.21 0.16 0.69
Age:Group 3 1.66 0.55 0.41 0.74
Residuals 60 80.52 1.34
Age 3 4.25 1.42 8.70 <0.001 PD-1
Group 1 3.11 3.11 19.10 <0.001
Age:Group 3 0.22 0.07 0.46 0.71
Residuals 60 9.78 0.16
Results of a repeated measures analysis of variance (ANOVA) to assess the effect of age (weeks 0–36) or HIV
exposure (Group), and the interaction between these two variables, on the frequency of expression of the listed T
cell markers by CD8 cells in CT infants. Pr<0.05 were considered significant.
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3.4 Discussion
Most studies of T cell markers between HEU and HU controls have been cross-
sectional studies (Table 3.5). For the most part, these studies reveal increased
activation profiles in HEU. In the present study, infants were followed up from birth
to 36 weeks of age enabling the simultaneous tracking of T cell markers over time
and differences in the expression of these markers between HEU and HU controls.
Overall, the kinetics of these T cell markers did not differ between exposure groups;
following similar patterns in peaking and waning. In cross-sectional analyses however,
HLA-DR expression by CD8 cells was increased in the HEU and CD25 significantly
increased after correction for FDR.
Maternal HIV infection has been associated with hyper inflammatory systemic
milieu [253, 237, 254], even in women on ART [255, 256]. Increased levels of soluble
inflammatory mediators have been found in the placenta of HIV infected mothers [237]
thereby providing potential stimulatory signals that may activate innate and adaptive
immune subsets [144]. Furthermore, higher levels of these maternal inflammatory
mediators correlate with increased risk of HIV transmission [237, 254]. While many
studies have compared levels of soluble inflammatory mediators between HIV infected,
cHEU and healthy controls, fewer studies have evaluated ex vivo T cell activation
between infants that are HIV-exposed and healthy un-exposed infants. Gut homing
CD4 cells, expressing the integrin α4β7 and co-expressing CCR5, a co-receptor for
HIV entry, were of interest as they are potential targets for HIV infection [244]
and may predict HIV acquisition [245]. In adult cohorts who are highly exposed
to HIV yet persistently sero-negative, HIV “resistance” is associated with reduced
absolute numbers of HLA-DR+ and CCR5 bearing CD4 cells ([257]. An important
study which tracked the frequencies of integrin α4β7 expression in peripheral blood
longitudinally, found that each 1% increase in integrin α4β7 expression prior to
acquisition was associated with a 17% increased risk of HIV acquisition [245] in
adults. In HIV-exposed infants, different mechanisms may be at play resulting in a
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potentially increased vulnerability to HIV infection. Animal models of mother to
child transmission of simian immunodeficiency virus (SIV) suggest that target cell
availability is the important determinant of reduced transmission rates observed in
Sootey Mangabeys—the natural hosts of SIV—compared to Rhesus macaques) [258].
The frequency of target cells (CD4+CCR5+) in the gut and peripheral blood were
significantly higher in frequently transmitting Rhesus macaques compared to rarely
transmitting Sootey mangebeys [258]. The human infant gut has an abundance of
potential HIV target cells [259], and CD4 cells from the cord blood of in utero HIV
exposed newborns which have been activated in vitro with soluble inflammatory
mediators, are more susceptible to HIV infection [144]. Crucially the induction of
HIV infectable cells by soluble factors in vitro was evident in women on supressive
ART with CD4 counts >200 cellsµL. The data presented here would be strengthened
by measuring in vivo maternal pro-inflammatory mediators which correlate with
increased HIV acquisition risk [237, 254]. BCG vaccination at birth was associated
with an increase in potential HIV target cells compared to delayed vaccination in
HIV-exposed infants in a randomised control trial [260]. However, compared to
unvaccinated animals, BCG-induced increases in target cells in Rhesus macaque
newborns did not translate to an increased SIV transmission via the oral mucosal
route compared to unvaccinated new borns [261]. In this study—where all infants
were BCG vaccinated at birth, we observed comparable increases in the frequencies of
CD4+CCR5hi cells between HEU and HU infants with age. No distinct differences in
the frequencies of these HIV target cells by HIV exposure group was found suggesting
that HEU infants are no more vulnerable to HIV infection (based on frequencies of
target cell) than their un-exposed peers.
In addition, we found no differences in "Treg-like" phenotypes between exposure
groups were seen in this study, with the caveat that FoxP3, a transcription factor
that programmes Tregs [262], was not included in the staining panel. Treg-like
phenotypes were described in this study as CD4+CD127lo+CD25+, as CD127
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inversely correlates with FoxP3 and suppressive function [247]. In highly HIV-
exposed yet uninfected adult cohorts has been defined by increase HIV-exposed
uninfected adults have increased circulating regulatory T cells that are thought to
contribute to their protection from HIV infection [263] and cHEU have increased
regulatory phenotypes that include CD4 expressing CD127lo and CD25hi [264] and
CD8 cells expressing markers FoxP3, TGF-β and IL-10 [140, 220]. Our findings
support those seen in a Kenyan cohort where cHEU and cHU had comparable
frequencies of CD4+CD25+FoxP3+ cells at 3 and 12 months of age [127]. It is worth
noting that while phenotypes of Treg-like cells may be comparable between exposure
groups, functionally they may differ and studies comparing the suppressive ability of
isolated Treg populations between cHEU and cHU infants are warranted.
The activation of T cells is critical component of adaptive immunity, where specific
extra-cellular and intracelluar proteins are upregulated on immune-competent cells
in response to antigen presentation. The levels of activation proteins alone or
in combination have been found to be useful surrogates for disease state, disease
susceptibility, antigen load and response to treatment [238, 239, 240, 241]. The
frequencies of Mtb antigen-specific cells expressing HLA-DR, CD38 or Ki67 markers
are able to discriminate active TB vs. latent TB disease states [239, 240] and the
expression of these markers on these Mtb responsive cells decrease with successful
TB treatment in those with active TB [240]. In bulk T cells however, higher baseline
HLA-DR expression is associated with an increased risk for TB disease [238]. On
the other extreme, significantly low levels of T cells expressing HLA-DR or CD25
may be a sign of malnutrition as illustrated in a recent study of neonates with severe
vitamin D compared to healthy controls [265]. Our findings of consistently higher
HLA-DR expression by CD8 cells among HEUs suggests that T cell activation is
induced in utero and persists to 36 weeks of life. This is supported by a number of
studies showing increased frequency of activated T cell phenotypes in the HEU infant
from birth [127, 132, 266, 267]. We did not measure the activation marker CD38 in
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this study, however other studies report increased CD38 among HEUs compared to
HU controls both by median fluorescence intensities (MFI) and frequency measures
[266, 118]. In one study by Rich and colleagues [132], no differences were found
between infant age-matched HEU and control groups in the expression of HLA-DR
alone, however levels of HLA-DR co-expressing CD38 T cells were up to 2-fold higher
among HEUs till 6 months of age. Only one study contradicts these findings where
HLA-DR+CD38+ co-expression among HEUs was lower compared to HUs at 6
months [268] however, the study in question was confounded by both sample size
comparisons (n=38 HEU vs. n=4 HU) and population differences (HEU cohort from
South Africa vs. HU cohort from North America). The most striking and significant
difference in activation phenotypes between HEU and HU was observed for CD25
(co-expressing CD127 to indicate activation). CD25 or IL-2Rα is a receptor with high
affinity for IL-2 cytokine signalling [269] and is upregulated upon antigen stimulation
requiring constant IL-2 signals for memory differentiation of virus-specific CD8 cells
[270]. To our knowledge, only one other study has compared CD25 expression as
an activation marker between HEU and HU, albeit on bulk T cells with no CD127
co-expression measured [132]. In that study, no differences in CD25 expression were
found between HEU and HU infants aged between than 6 months. Whether this
increased activation is a direct consequence of exposure to inflammatory mediators
in the HEU, virus or other environmental antigens and whether this is a marker
for increased risk of infection was not directly addressed in this study. Our results
nonetheless suggest that CD8 T cells in particular are activated in the HEU during
the first 36 weeks of life.
To summarise, the strongest ex vivo T cell marker signals that differentiated cHEU
infants from their unexposed counter parts in this study was increased expression of













































































































































































































































































































































































































































































































































































































































































































































































































































T cell function in HEU
infants—vaccine immunogenicity
4.1 Introduction
There is reliable evidence that cHEUs are capable of mounting seroprotective antibody
titres following vaccination [123, 114], however, the ability of cHEUs to mount robust
T cell responses of comparable magnitude and quality to HIV-unexposed infants
unclear [79], particularly in the Option B+ era. While T cell correlates of vaccine
protection in humans are not well defined for the vaccine antigens measured in this
study, we propose to measure the magnitude and quality of Th1 cytokines as a
proxy for T cell function—comparing cHEU with cHU control groups over the first 9
months of life. Th1 cytokines are induced by BCG [186], Tetanus Toxoid [206] and
both acellular and whole cell forms of Pertussis vaccines [206, 213]. The read-outs
for the majority of studies evaluating cell-meditated functional responses in cHEUs
are derived from long-term in vitro culture assays, but these studies have yielded
inconsistent findings [126, 40, 128, 129, 130]. Some studies report no impairment
in the production of cytokines following antigen stimulation [40, 126], while others
report either significant impairment [128, 271] or paradoxically, enhanced cytokine
73
production in cHEUs [129]. These long-term assays have a number of limitations
which confound the interpretation of their data. Firstly, these assays require that
the cells proliferate and are viable (often after several days in culture); secondly, the
cellular source of secreted factors into culture media is unknown, unless intracellular
cytokine staining is used. Furthermore, to detect intracellular cytokines after long-
term culture requires re-stimulation of cells with super antigen in the final hours of the
assay, thus confounding the interpretation of antigen specificity. The short-term whole
blood assay proposed for use here, allows for the identification of re-call responses in
physiological conditions that are similar to those in vivo [138]. The major differences
in this proposed present study from other published work include the following: (i)
leverage of two independent birth cohorts to test the hypothesis that HIV exposure
alters vaccine immunity; (ii) application of several analytical techniques to measure
the magnitude and quality of vaccine-induced immunity—combined with robust
statistical methods to account for type 1 error; (iii) measurement of three vaccine
antigens in the same assay, two of which (Tetanus Toxoid and Bordetella pertussis
antigens) have not routinely been measured in cell-mediated studies in HEUs and
(iv) the study involved breastfed infants of mothers on suppressive ART.
4.2 Methods
4.2.1 Cohort description
Mother-infant pairs were recruited at the Midwifery Obstetric Unit (MOU) at Site
B in Khayelitsha, Cape Town (CT), South Africa and the Plateau State Specialist
Hospital in Jos, Nigeria from November 2014 to November 2016 (Table 4.1). Infants
were followed from birth, at day 4–7 and at weeks 7, 15 and 36 of life. Pretest
counselling and HIV testing was done at the time of antenatal care registration. Both
mothers with and without HIV infection were eligible for the study. Mothers with
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HIV and their infants were provided with ARV according to the current country-
specific guidelines [224, 223]. All mothers in the study were of consenting age and
provided written informed consent. Exclusive breastfeeding (EBF) was advised to
all mothers from the time of delivery to 6 months. Breastfeeding rates to 6 months
of age between HEU and HU groups for the entire study cohort were 81% and 88%
respectively (Table 7.1). Infants born before 36 weeks and with birth weights lower
than 2.4 kilograms were ineligible for the study. Further exclusion criteria included
pregnancy or delivery complications as previously described [194]. All HEU babies
were confirmed as negative by PCR at birth and at 6 weeks of age according to
PMTCT guidelines [224, 223]. A total of 186 HEU and 97 HU infants across the two
cohort sites were included in the analysis for this chapter.
4.2.2 Immunisation
Routine vaccines were given to all infants according to the WHO’s EPI (Table 4.1).
Infants from CT received intradermal Danish BCG strain (1331, Statens Serum
Institute, Denmark) from April 2013 to January 2016 and thereafter Russian strain
(BCG-I Moscow, Serum Institute of India, India). Both strains were given at 2×
105 CFU/dose at birth. Infants from Jos received the Bulgarian strain (BCG-SL
222 Sofia, BB-NCIPD Ltd, Bulgaria) at 0.3× 105 CFU/dose and due to logistical
reasons were vaccinated between 4-7 days after birth. Diptheria-Tetanus-acellular
Pertussis (DTaP) or whole-cell Pertussis (DTwP) vaccines were administered at 6,
10 and 14 weeks in Cape Town and Nigerian respectively. Other routine vaccines
and their schedules are listed in Table 4.1 below.
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Table 4.1: Infant vaccination schedule and whole blood assay testing





10 DTaP, Hib/HBV DTwP/Hib/HBV/OPV
14 DTaP/Hib/Rota/PCV/HBV DTwP/Hib/IPV/PCV
15 BCG/TT/BP
36 Measles/PCV Measles/YFV BCG/TT/BP
Vaccine schedule by infant age (in weeks) and cohort site. BCG (Bacille-Calmette Guerin), †Denmark/Russia
strains, ‡Bulgaria strain, DTaP (Diptheria-Tetanus-acellular Pertusiss, DTwP (Diptheria-Tetanus-whole cell Pertu-
siss), OPV (Oral Polio vaccine), Hib (Haemophilus influenzae type b), HBV (Hepatitis B vaccine), IPV (Inactivated
polio vaccine), PCV (Pneumococcal conjugate vaccine), YFV (Yellow fever vaccine). WBA test antigens: BCG
(Bacille-Calmette Guerin), TT (Tetanus Toxoid antigen), BP (Bordetella Pertussis antigens)
4.2.3 Whole blood assay and whole blood fixing
For T cell vaccine measurements, a 12-hour whole blood assay was used [138]. Briefly,
250 µL of anticoagulated blood was incubated with vaccine antigens or PHA at
37◦C within one hour of blood draw. For BCG stimulation, 12 x 105 CFU/mL of
Mycobacterium bovis was reconstituted in RPMI media from either the vaccine vial
(BCG-Denmark strain 1331: SSI or BCG-SL 222 Sofia strain: BB-NCIPD) or live
BCG culture (BCG-Denmark strain 1331: AJVaccines, Denmark)(see Table 7.3).
Other stimuli included Tetanus Toxoid (TT) antigens (Sanofi Pasteur) at 5 IU/mL
and 0.01% v/v of Bordetella pertussis (BP) antigens (BD Difco). Phytohemagglutinin
(PHA) (50 µg/mL) or RPMI with 10% fetal calf serum (FCS) were used as positive
and negative controls respectively. After 5 hours, Brefeldin-A (Sigma Aldrich) was
added to a final concentration of 10 µg/mL and incubated for an additional 7
hours. Thereafter, red blood cells were lysed followed by washing and staining with
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LIVE/DEAD R© fixable Violet stain (ViViD, ThermoFisher). For the CT samples,
cells were cryo-preserved in 10% DMSO and 90 FCS and stored immediately in liquid
nitrogen (LN2). For Jos samples, cells were cryo-preserved in 10% DMSO and 90%
FCS, stored at -70◦C and shipped within 6 months to the University of Cape Town
(UCT) and then transferred to LN2. Analysis of all samples was performed at the
core laboratory at the UCT.
4.2.4 Cell staining, antibodies and flow cytometry
Batched stored samples were thawed quickly at 37◦C and washed twice with 1× BD
PermWash buffer. Cells were then incubated in 1× BD PermWash for 10 minutes
before incubation with the antibody cocktail mix in 2% FCS in PBS at 4◦C for 45
minutes. After incubation, cells were washed twice with in 2% FCS in PBS and the
resuspended in 2% FCS in PBS for cell acquisition using a Beckton Dickinson LSRII
flow cytometer (SORF model). The following monoclonal antibody-fluorochrome
conjugates were used in the T cell vaccine panel: IL-2-R-phycoerythrin (PE), CD8-
V500, IFN-Alexa Fluor-700, TNF-α-PE-Cy7, Ki67-Fluorescein isothiocyanate (FITC;
BD), CD27 PE-Cy5, HLA-DR- Allophycocyanin-Cy7 (APC-Cy7), CD3-BV650 (all
from Biolegend), CD4 PE-Cy5.5 (Invitrogen), CD45RA PE-Texas Red-X (Beckman
Coulter). A minimum of 50 000 ViViD negative (viable) CD3 events were collected
for T cell vaccine measurements using FACS DIVA v6 software. Post-acquisition
compensation and analysis was performed in FlowJo version 9 (FlowJo, LLC). Figure
4.1 shows the gating strategy employed for T cell vaccine responses. Total cytokine
frequencies were from the total T cell population and based on boolean combinations
of the 3 gated cytokine populations.
4.2.5 Statistical analyses
Statistical analyses of flow cytometry data was performed in R [249], SPICE soft-
ware [272]. Non-parametric comparisons between two independent groups was
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performed using Wilcoxon Rank Sum test (Mann Whitney U test). A repeated mea-
sures analysis of variance (ANOVA) or Kruskal Wallis tests were used for longitudinal
data. The Holm’s step down method was used for multiple comparison correction.
For differences by exposure groups for qualitative measures of vaccine immunity we
used SPICE software. Only antigen responders were selected (Appendix 7.7) with
the following threshold set: each sample’s stimulated cytokine frequency had to
be greater than its unstimulated cytokine frequency and at least 2× unstimulated
cytokine frequency. These were then background subtracted in the SPICE workflow
before group comparisons were made.
4.3 Results
4.3.1 Detection of post-vaccination antigen responses
To determine which time-points the whole blood assay was able to detect vaccine-
induced responses (above background), we compared total cytokine producing CD4
frequencies between unstimulated and vaccine antigen-stimulated samples for the en-
tire data set (CT and Jos infants) across all time-points measured. Only participants
with matching unstimulated - stimulated pairs were used in these analyses (Figure
4.2). Figure 4.1 shows the gating strategy used to define T cell cytokine responses.
We defined time points with detectable antigen responses if the following criteria
were met at each time point: (i) the median frequency of cytokine+ cells was greater
than the median frequency of cytokine+ cells in background samples (unstimulated)
and (ii) differences between unstimulated and simulated magnitudes were statisti-
cally significant after FDR adjustment. Cytokine frequencies in antigen-stimulated
samples were indistinguishable from unstimulated samples at pre-vaccination time
points (Table 4.2 and Figure 4.2). For BCG, detectable responses were at 7, 15- and
36-weeks post BCG vaccination with median CD4 cytokine frequencies in unstimu-
lated and BCG-stimulated samples as follows: at week 7 (0.07 and 0.50, respectively
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p<0.001), at week 15 (0.07 and 0.28, respectively p<0.001) and at week 36 (0.06
and 0.16, respectively p<0.001). Detectable TT responses were observed at 15-
and 36-weeks post BCG median CD4 cytokine frequencies in unstimulated and
TT-stimulated samples as follows: at week 7/ 1 week DTaP/wP (0.06 and 0.08
respectively, p=0.005), at week 15/ 5 weeks post 2nd DTaP/wP (0.08 and 0.14,
p<0.001) and at week 36/ 24 weeks post 3rd DTaP/wP (0.06 and 0.13, p<0.0001).
BP responses were significantly above background for 7, 15- and 36-weeks post BCG
where median frequencies of CD4 cytokine cells between unstim and BP antigens
were: week 7/ 1 week DTaP/wP (0.06 and 0.10 respectively, p<0.001), week 15/ 5
weeks post 2nd DTaP/wP (0.08 and 0.11, p<0.001), week 36/ 24 weeks post 3rd
DTaP/wP (0.06 and 0.1, p<0.001). In summary, BCG responses were detected at
7 weeks post BCG and thereafter, TT responses were detectable at 15 weeks post







































Figure 4.1: Flow cytometry gating strategy to define T cell cytokine responses to antigen
stimulation. Singlets and lymphocytes were defined by forward (FSC-A) and side scat-
ter (SSC-A) properties. Flow acquisition artefacts were gated out for each parameter
in time gates. Cytokine responses were measured from the parent CD4+ population.
Cytokine memory subsets were quantified from parent CD4 population to boolean com-
binations of cytokine+ cells. Memory subsets were defined by CD45RA and CD27 such
that CD45RA+CD27+ represent naïve-like, CD45RA-CD27+ early differentiated (ED),
CD45RA-CD27- late differentiated (LD) and CD45RA+CD27- terminally differentiated
(TD) memory phenotypes.
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Figure 4.2: Whole blood assay detection of vaccine-specific responses. The magnitude
of CD4 cytokine+ frequencies are compared between unstimulated (red points) and vac-
cine antigens (A) BCG, (B) Tetanus Toxoid (TT) and (C) Bordetella pertussis (BP)
antigen-stimulated samples (turquoise points). Strip-panel text indicate weeks post BCG
vaccination. For TT and BP antigens 1 wk BCG = -5 wk pre-DTaP/wP, 7 wk BCG =
1 wk post 1st DTaP/wP, 15 wk BCG = 5 weeks post 2nd DTaP/wP, 36 wk BCG = 24
weeks post 3rd DTaP/wP (Table 4.1). A paired Wilcoxon-rank Sum test was used to
test differences between unstimulated and antigen stimulated conditions and unadjusted
p-values comparing the groups are shown. P<0.001 were considered significant after FDR
correction. 81
Table 4.2: Pre-post vaccination frequencies of CD4+cytokine+ cells
% of CD4 cytokine+
Antigen BCG wk DTaP/wP wk Stim n median IQR1 IQR2
BCG 0 unstim 51 0.05 0.01 0.09
BCG 51 0.05 0.02 0.08
1 unstim 28 0.06 0.03 0.09
BCG 28 0.10 0.02 0.18
7 unstim 143 0.07 0.01 0.16
BCG 143 0.51 0.07 0.95
15 unstim 118 0.07 0.02 0.13
BCG 118 0.28 0.07 0.50
36 unstim 102 0.06 0.01 0.11
BCG 102 0.16 0.05 0.27
TT 1 -5 pre 1st dose unstim 28 0.06 0.03 0.10
TT 28 0.08 0.02 0.17
7 1 post 1st dose unstim 124 0.06 0.01 0.12
TT 124 0.08 0.03 0.14
15 5 post 2nd dose unstim 113 0.08 0.02 0.13
TT 113 0.14 0.03 0.24
36 24 post 3rd dose unstim 96 0.06 0.02 0.10
TT 96 0.13 0.03 0.23
BP 1 -5 pre 1st dose unstim 29 0.06 0.03 0.10
BP 29 0.07 0.03 0.11
7 1 post 1st dose unstim 107 0.06 0.00 0.11
BP 107 0.10 0.06 0.15
15 5 post 2nd dose unstim 105 0.08 0.02 0.13
BP 105 0.11 0.04 0.18
36 24 post 3rd dose unstim 89 0.06 0.01 0.11
BP 89 0.10 0.04 0.16
Median frequencies of CD4 cells expressing total cytokines are shown for unstimulated
and vaccine antigen-stimulated conditions with upper and lower interquartile ranges (IQR1
and IQR2 respectively). Data is combined for CT and Jos infants. BCG vaccination
weeks (BCG wk) are indicated with corresponding Diptheria-Tetanus-acellular/whole-cell
Pertussis vaccination week (DTaP/wP wk). Time-points where vaccine-antigen frequencies
that were significantly greater than unstimulated samples after paired Wilcoxon Rank Sum
tests and multiple comparison adjustment (p-adjusted<0.05) are indicated in bold.
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4.3.2 Magnitude of T cell vaccine-antigen responses are similar be-
tween cHEU and cHU
We compared the CD4 cytokine frequencies of antigen responses between HEU and
HU groups across all time-points measured to determine whether exposure had an
impact of the magnitude of total cytokines, stratifying responses by cohort site. There
were no differences in the magnitude of background (cytokine+ cells in unstimulated
condition) by HIV exposure status. Importantly, the magnitudes of CD4 responses











































































































Figure 4.3: Magnitude of T cell vaccine-antigen responses are similar between cHEU and
cHU. Cross-sectional comparison of total CD4 T cell cytokine responses (IFN-γ, TNF-α
or IL-2) to in vitro antigen stimulation: (A) BCG, (B) Tetanus Toxoid (TT) and (C)
Bordetella pertussis (BP) between HEU (maroon points) and HU (grey points) groups.
Shaded bars show the median background per group and per time point. Strip text at the
top indicates weeks post BCG and the strip text on right-hand side indicate the cohort.
For TT and BP antigens 1wk BCG = 5 wk pre-DTaP/wP, 7 wk BCG = 1 wk DTaP/wP,
15 wk BCG = 9 wk DTaP/wP, 36 wk BCG = 30 wk DTaP/wP. Wilcoxon ranked sum
tests were used to compare HEU and HU goups and p<0.01 were considered significant
after adjusting for multiple comparisons using Holm’s step-down method.
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4.3.3 Subtle differences in cytokine profiles to vaccine antigens in
cHEU: SPICE analysis results
Having established that response magnitudes were unaffected by HIV exposure, we
next asked whether the profiles of Th1 cytokines induced by vaccine antigens in vitro
(combinations of IFN-γ, TNF-α or IL-2) were altered compared to controls (Figures
4.4–4.8). We started with SPICE analysis (Simplified Presentation of Incredibly
Complex Evaluations)[272]. For CT infants, BCG induced cytokine patterns that
included dual and triple positive (polyfunctional) CD4 cells at weeks 7, 15 and 36
post BCG vaccination (Figure 4.4). These patterns differed between cHEU and
cHU infants only at one week post BCG vaccination in CT infants (Figure 4.7A)
where the majority of the cytokine response among HEUs was TNF-α compared to
HUs (p=0.03). In contrast, HUs predominantly expressed IFN-γ relative to HEUs
(p=0.08). These differences in mycobacterial-specific cytokines were evident despite
comparable magnitudes in the total CD4 response (Figure 4.7B). Differences in the
patterns of cytokine expression between HIV exposure groups were also evident for
BP antigen among CT infants at week 36 (Figure 4.6) despite no differences in the
magnitude of the total CD4 response (Figure 4.3). At week 36, HEUs had lower
single positive TNF-α as a proportion of the total cytokine response compared to
HUs (p=0.007: Figure 4.6). For Jos infants, the cytokine patterns induced by BCG
were in stark contrast to that of CT infants, where less dual and polyfunctional CD4
cells were observed. However, cytokine profiles between HEU and HU were largely
comparable at all time points post BCG (Figure 4.6). Similar to CT infants, BP
antigen induced slight changes in overall cytokine patterns between HEU and HU
groups in Jos. These differences were at week 36 (p=0.01) where HEU expressed a
greater proportions of single positive IFN-γ (p=0.007) CD4 cells compared to the
cHU respectively (Figure 4.6). Cytokine patterns induced by TT antigen did not
differ by HIV exposure among Jos infants (Figure 4.5). CT infants showed marginal
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differences in cytokine patterns between cHEU and cHU responding to TT antigen
at week 36 (p=0.09; Figure 4.5), where cHU had greater proportions of dual positive
TNF-α+IL-2+ (p=0.02) and less single positive IFN-γ (p=0.03) CD4 cells, though
this did not pass signficance in adjusted analyses.
In summary cytokine patterns induced by BCG were significantly different by
HIV exposure only at 1 week after BCG vaccination (only observed in CT infants).
Moderate differences in cytokine patterns by HIV exposure status were for TT
antigen (in CT infants at week 36) and BP (at weeks 7 and 36 for Jos and CT
respectively) but these did not reach significance in adjusted analyses. Combined
these results show that whilst modest qualitative differences in vaccine responses can
be observed between cHEU and cHU, the most significant differences occurs early
within the first week of life.
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Figure 4.4: BCG-specific cytokine profiles by HIV exposure status. CT infant responses
are shown on the left and JOS infant responses on the right. Scatter plots show the
frequency of CD4 cells expressing each boolean cytokine combination (G = IFN-γ, 2 =
IL-2, T = TNF-α) with each combination numbered 1-7 in colour blocks below each graph.
Scatter dots are colour-coded by HIV exposure status (maroon dots: cHEU, grey dots:
cHU). Shaded grey bars show inter-quartile ranges with black line showing medians. Pie
charts show median proportions of each cytokine combination (1-7) as a fraction of the total
response with each pie slice colour corresponding to the colour blocks below the scatter
plots. Pie charts are compared using the SPICE permutations test with p<0.01 considered
significant and each boolean cytokine combination was compared using a Wilcoxon Ranked
Sum Test with p<0.01 were considered significant.
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Figure 4.5: Tetanus Toxoid-specific (TT) cytokine profiles by HIV exposure status. CT
infant responses are shown on the left and JOS infant responses on the right. Scatter plots
show the frequency of CD4 cells expressing each boolean cytokine combination (G=IFN-γ,
2=IL-2, T=TNF-α) with each combination numbered 1-7 in colour blocks below each
graph. Scatter dots are colour-coded by HIV exposure status (maroon dots: cHEU, grey
dots: cHU). Shaded grey bars show inter-quartile ranges with black line showing medians.
Pie charts show median proportions of each cytokine combination (1-7) as a fraction of the
total response with each pie slice colour corresponding to the colour blocks below the scatter
plots. Pie charts are compared using the SPICE permutations test with p<0.01 considered
significant and each boolean cytokine combination was compared using a Wilcoxon Ranked
Sum Test with p<0.01 were considered significant.
88







































































































































































































Group: HEU Group: HU































































































Group: HEU Group: HU
HEU HU
0.75
Group: HEU Group: HU
0.007
Figure 4.6: Bordetella pertussis-specific (BP) cytokine profiles by HIV exposure status.
CT infants vaccinated with acellular Pertussis (aP) and are shown on the left whereas
Jos infants were vaccinated with wP (whole-cell Pertussis) and are shown on the right.
Scatter plots show the frequency of CD4 cells expressing each boolean cytokine combination
(G=IFN-γ, 2=IL-2, T=TNF-α) with each combination numbered 1-7 in colour blocks below
each graph. Scatter dots are colour-coded by HIV exposure status (maroon dots: cHEU,
grey dots: cHU). Shaded grey bars show inter-quartile ranges with black line showing
medians. Pie charts show median proportions of each cytokine combination (1-7) as a
fraction of the total response with each pie slice colour corresponding to the colour blocks
below the scatter plots. Pie charts are compared using the SPICE permutations test with
p<0.01 considered significant and each boolean cytokine combination was compared using
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Figure 4.7: Early differences in single cytokine profiles to mycobacterial antigen among
HEUs despite parity in total cytokine frequencies. (A) & (C) BCG-specific and PHA-
specific cytokine profiles respectively for CT infants. SPICE dot plots show the frequency
of CD4 cells expressing each cytokine boolean cytokine combination (G=IFN-γ, 2=IL-2,
T=TNF-α) and are colour-coded by HIV exposure status (maroon circles: HEU, grey
circles: HU). Shaded grey bars show interquartile ranges with line showing medians. Pie
charts show median proportions of each cytokine combination as a fraction of the total
response strain group by SPICE analysis. Pie charts are compared using the SPICE
permutations test with p<0.01 considered significant. Cytokine combination subsets were
compared using a Wilcoxon Ranked Sum Test with p<0.01 were considered significant.
(B) & (D) Week 1 CD4 response magnitude to BCG and PHA by HIV exposure status
respectively. Y axes show the frequency of CD4 cells producing total cytokine (IFN-γ,
TNF-α or IL-2). Shaded bars show the median frequency in the unstimulated samples.
Wilcoxon ranked sum tests were used to compare HEU and HU groups with p<0.01 were
considered significant.
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4.3.4 Trend towards increased polyfunctional and functional scores
in cHEU: COMPASS analysis results
We complimented the SPICE analyses of the quality of vaccine responses by HIV
exposure with a computational algorithm for an unbiased combinatorial polyfunction-
ality analysis of antigen-specific T-cell subsets (COMPASS) [273]. COMPASS models
the probability of antigen-specific responses (posterior probabilities) for each possible
combination of cytokine subsets, assigning small probabilities to subsets that are
least likely to be present for a particular individual which can be viewed as a heatmap
(Figure 4.8). COMPASS also assigns functional scores (FS) for each individual—a
summary statistic that quantifies all possible functional subsets. COMPASS also
assigns polyfunctional scores (PFS)—a similar summary statistic to FS but weighted
to polyfunctional (2 or more cytokines). These scores are continuous variables that
can be compared between phenotypes, time points etc. and are statistically more
robust than SPICE analyses. As shown in Figure 4.9, two main observations were
apparent: firstly, the majority of polyfunctional and functional scores to vaccine
antigens were equal between HEUs and HUs, secondly, where there were differences,
these tended to reflect higher—rather than lower polyfunctional/functional scores
among HEUs. For example at week 15, HEUs in the Jos cohort had higher PFS to
mycobacterial antigen compared to HUs (median 0.23 vs. 0.07 respectively, p=0.01)
and concomitant FS (median 0.32 vs. 0.17 respectively, p=0.03). Similar trends
in higher PFS among HEUs were observed for responses to BP antigen in CT in-
fants at week 36 (median 0.1 vs. 0.04 respectively, p=0.03) and concomitant FS
(median 0.18 vs. 0.08 respectively, p=0.03). These results however, did not pass
multiple comparison correction. COMPASS analyses on the whole reflected findings
in SPICE analyses which showed no alterations to TT antigen but subtle differences
to BP antigen. In summary, COMPASS analyses suggest no convincing immune

















































































Figure 4.8: Heatmap of posterior probabilities of antigen responses estimated by COM-
PASS analysis. Heatmaps for (A) BCG, (B) TT = Tetanus Toxoid and (C) BP = Bordetella
pertussis antigens. Rows represent individual infants and grouped by HIV exposure status
and time post BCG vaccination (colour-coded annotations on right side of heat map).
Columns represent cytokine subsets (combinations) ordered by degree of functionality
(single to polyfunctional; right to left). The colour of each cell corresponds to the probability
(range 0-1) of an antigen response for a particular cytokine cell subset per infant, with 1





















































































































































Figure 4.9: Trend towards increased polyfunctional and functional scores in HEUs. Scatter
plots show COMPASS analyses for polyfunctional scores (PFS: column 1) and functional
scores (FS: column 2) of antigen specific responses: (A) & (B) BCG, (C) & (D) TT =
Tetanus Toxoid and (E) & (F) BP = Bordetella pertussis antigens. Maroon points =
HIV-exposed uninfected (HEU) and grey points = HIV-unexposed (HU). P-adjusted values




In this section, we found that the impact of HIV exposure on cell-mediated vaccine
responses appeared to be limited to partial qualitative differences rather than differ-
ences in the response magnitude. While some studies have suggested quantitative
differences between HEU and HU groups [130, 126, 127, 140], we found no such
evidence. The unique aspect of our study was that this observation was replicated in
two independent cohorts. The cohorts in this study are from derived from communi-
ties where Mtb infection is common [274, 275], therefore, the functional capacity of
mycobacterial-specific T cells from HEUs was of particular interest, specifically the
induction of polyfunctional T cells which correlate with enhanced Mtb protection
in animal models [135]. Polyfunctional T cell responses to vaccination against Mtb
are the focus of novel Tb vaccination strategies [197]. Others have reported differ-
ences in mycobacterial polyfunctional responses between HEU and HU infants—in
proliferating T cells [128]. SPICE analyses in this study revealed differences in the
proportions of single cytokines one week after BCG vaccination, whereas polyfunc-
tionality assessed by COMPASS polyfunctional scores suggest that T cells from
HEUs are equally immune competent as HUs in responding to mycobacterial antigen.
The absence of any qualitative differences to mycobacterial antigen beyond the first
month of life has also been shown in both Ugandan and South African cohorts,
vaccinated with BCG at birth [131, 127].
Interestingly, we detected marginal qualitative differences for Bordetella pertussis,
with higher polyfunctional scores among HEUs, suggesting immune competance to
this vaccine. An important consideration here is that our cohorts were under Option
B+ where all HIV+ women received ART during pregnancy and thereafter. In
addition, exclusive breastfeeding rates (up to 6 months of age) were high compared
to other studies [83, 100] which improves clinical outcomes in these infants [194]. In
summary, we found no convincing evidence for perturbations in both the magnitude
and quality of vaccine responses by HIV exposure. Instead, we observed far greater
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differences in vaccine immunogencity by cohort site, particularly for BCG, where Jos
infants tended to have lower overall cytokine production compared to CT infants
and lower polyfunctional scores (Appendix 7.4 and 7.5). This appears to support the
observation that responses to mycobacterial antigen from cohorts closer to the tropics
tend to exhibit lower Th1 cytokine profiles than those further from the tropics [276,
36]. We do acknowledge that sample integrity (related to cold-chain) may have been
a contributing factor in explaining the lower cytokine responses for the Jos cohort.
Nonetheless, within-cohort comparisons of cytokine frequencies between HEU and
HU groups suggest that exposure does not affect the magnitude of response.
Overall the data presented in this chapter suggests that T cell function is normal-
ized after the first week of life and that HIV/ARV exposure may have no deleterious
long-term impact on vaccine immunogenicity.
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Chapter 5
Impact of BCG immunising strain on
T cell function
5.1 Introduction
In Chapter 4, CD4 cytokine responses to vaccine antigens were compared between
cHEU and cHU from two African cohorts. Substantial differences were noted in the
frequencies of CD4+cytokine+ cells and polyfunctional scores (by COMPASS) for
mycobacterial responses between cohorts (Appendices 7.4 & 7.5), irrespective of HIV
exposure status which warranted further investigation. CT infants recruited in this
study had received BCG-Denmark until January 2016 when BCG-Denmark became
unavailable and the South African EPI program began using BCG-Russia. BCG-
Russia is genetically identical to BCG-Bulgaria [277], the strain given to infants in
Nigeria. In this observational study, we leveraged the change to EPI BCG immunising
strain to test the hypothesis that immunogenicity to BCG-Denmark would differ to
that of Russian and Bulgarian BCG immunised infants.
Many TB endemic countries provide Bacille Calmette-Guérin (BCG) vaccine to
infants routinely soon after birth [192, 188, 278, 128]. BCG is efficacious against child-
hood TB, particularly extrapulmonary forms [279]. Numerous strains of BCG exist,
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with various duplications and deletions in protein coding regions [280], which have
been shown to affect the type of immunity elicited by the vaccine [192, 281]. Although
no correlate of protection against Mycobacterium tuberculosis (Mtb) exists [186],
Th1 CD4+ T cells are believed to be important [282, 283] and are therefore used to
measure BCG vaccine immunogenicity [192, 128, 281, 187, 131, 194, 127]. BCG-
Denmark strain has been shown to induce a greater magnitude and polyfunctional
CD4+ Th1 cytokine production [281] and also has a range of heterologous effects [278,
284, 285, 286]. For example, in adults, BCG-Denmark increases monocyte cytokine
production against unrelated antigen stimulation; where such “trained immunity”
after primary infection or vaccination has been shown to confer protection against
secondary infection, independent of the adaptive immunity [285]. In adults vaccinated
with BCG-Denmark, increases Th1 and Th17 cells are observed in response to in vitro
stimulation with heterologous antigen [287]. BCG-Denmark vaccinated infants have
higher IFN-γ responses to Phytohaemagglutinin (PHA) and Tetanus Toxoid (TT)
versus those vaccinated with BCG-Russia in cultured whole blood supernatants [286].
In low birth weight infants, BCG-Denmark vaccination has been associated with
increased innate cytokine levels in whole blood stimulated with Toll-like receptor
(TLR) ligands [288]. Whether vaccine strains other than BCG-Denmark have a
similar effect on T cell responses to unrelated antigens in African infants has not
been assessed. In this study, we compared CD4+ T cell immunity to BCG, Tetanus
and Pertussis vaccines in two cohorts of newborn infants recruited from Jos, Nigeria
and Khayelitsha, Cape Town, South Africa (Methods section 4.2.1: Chapter 4), and
interrogated the effects of BCG strain. We show that BCG vaccine strain not only
impacts significantly on CD4+ T cell polyfunction and memory maturation, but also





Mother-infant pairs were recruited at the Midwifery Obstetric Unit (MOU) at Site
B in Khayelitsha, Cape Town (CT), South Africa and the Plateau State Specialist
Hospital in Jos, Nigeria from November 2014 to November 2016 as described in detail
in section 4.2.1.
5.2.2 Immunisation
Routine vaccines were given to all infants according to National Vaccine programme
guidelines (Table 4.1). Infants from CT received intradermal Danish BCG strain
(1331, Statens Serum Institute, Denmark) from April 2013 to January 2016 and
thereafter Russian strain (BCG-I Moscow, Serum Institute of India, India). Both
strains were given at 2×105 CFU/dose at birth. Infants from Jos received the Bul-
garian strain (BCG-SL 222 Sofia, BB-NCIPD Ltd., Bulgaria) at 0.3×105 CFU/dose
at 4–7 days after birth (Table 7.3).
5.2.3 Whole blood assay
A 12-hour whole blood assay was used to evaluate vaccine responses as previously
described in Chapter 4, section 4.2.3. The in vivo vaccine dose and whole blood
assay antigen concentrations are listed in Table 7.3.
5.2.4 Cell staining, antibodies and flow cytometry
For vaccine immunogencity measurements, cell staining and flow cytometery was car-
ried out as described in Chapter 2, section 4.2.4. The following monoclonal antibody-
fluorochrome conjugates were used in the T cell vaccine panel: IL-2-R-phycoerythrin
(PE), CD8-V500, IFN-γ-Alexa Fluor-700, TNF-α-PE-Cy7, Ki67-Fluorescein isoth-
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iocyanate (FITC) (all from BD), CD27 PE-Cy5, HLA-DR- Allophycocyanin-Cy7
(APC-Cy7), CD3-BV650 (Biolegend), CD4 PE-Cy5.5 (all from Invitrogen), CD45RA
PE-Texas Red-X (Beckman Coulter). A minimum of 50 000 ViViD negative (viable)
CD3 events were collected for T cell vaccine measurements using FACS DIVA v6
software. Post-acquisition compensation and analysis was performed in FlowJo
version 9 (FlowJo, LLC).
5.2.5 Statistical analyses
Participant BCG-strain and HIV exposure groupings were unblinded after flow-
gating analyses. All statistical analyses were performed in R [249]. Non-parametric
comparisons between independent groups was performed using Wilcoxon rank sum
test (Mann Whitney U test), with the Holm’s step down method used for multiple
comparison correction. The Kruskal Wallis test was used for longitudinal data. For
cytokine profiling analyses in SPICE, we only analysed samples from participants
classified as antigen responders (Figure 7.7) to avoid skewing related to samples
that were likely to be background. Cytokine combinations were assessed using
SPICE software [272] and in addition, we used a more unbiased statistical approach
for measuring polyfunctionality with COMPASS (Combinatorial polyfunctionality
analysis of antigen- specific T-cell subsets) [289] to estimate the posterior probabilities
of antigen specific T cell subsets. COMPASS is a statistical model for multi-functional
(e.g. multiple cytokine subsets) analysis of flow cytometry data sets. Polyfunctionality
scores which summarize the functional profile of each subject were calculated from




A total of 186 samples from CT and 84 samples from Jos spanning the first nine
months of life were included in this study (Table 5.1). There were no differences in
gestational age at delivery, birth weight or baby length by vaccine strain received
(i.e BCG-Denmark, BCG-Bulgaria or BCG-Russia).
Table 5.1: Infant birth characteristics by BCG immunising strain received at birth
BCG strain
Bulgaria (N=84) Denmark (N=154) Russia (N=32) P-values
Age (weeks) 38 [38-39] 38 (37-39) 38 [38-39] 0.22
Birth weight (g) 3000 [2700-3300] 3025 [2778-3330] 2930 [2840-3230] 0.16
Length (cm) 47 [46-49] 48 [46-50] 47 [46-50] 0.1
Female (%) 41 58 57 0.29
HEU (%) 78 68 54 0.03
BCG-Denmark and BCG-Russia were infants from the Cape Town cohort, BCG-Bulgaria were infants from Jos
cohort. Numbers represent median with interquartile ranges in brackets. Wilcoxon Rank Sum test was used to
compare strains for continuous variables (B-D; Bulgarian vs. Danish, D-R; Danish vs. Russian). P<0.05 were
considered significant. Chi Squared test for homogeneity was used for categorical variables
5.3.2 Magnitude of mycobacterial-specific CD4 T cell cytokine re-
sponses differ according to BCG strain
The rationale for comparing responses by BCG strain was due to the observation of
lower response magnitudes among Jos infants (all having received BCG-Bulgaria) vs.
CT infants (the majority of whom had received BCG-Denmark at birth: Table 4.1).
Infant whole blood samples had been re-stimulated in vitro with the vaccine-matched
antigen, except cells from CT infants vaccinated with BCG-Russia were stimulated
with BCG-Denmark culture (SSI) in vitro (Appendix 7.3). We confirmed that the
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in vitro stimulating antigen did not impact the magnitude of quality of the T cell
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Figure 5.1: The in vitro simulating antigen does not impact response magnitude or quality. The unavailability of BCG
SSI Denmark (SSI, Denmark) for laboratory assays necessitated the switch to BCG-Denmark culture (AJ Vaccines)
for in vitro stimulation. Different in vitro concentrations of BCG culture were compared to the standard BCG
vaccine in vitro concentration used in whole blood assay for CT infants. Donors representing different week 7 and
week 15 post BCG time points were used in the same experiment. Total CD4 cytokine frequencies are shown in the
dot plots and median proportions of each cytokine (IFN-γ, IL-2 and TNF-α) are represented by the pies.
Due to the unequal distribution of HEU vs. HU infants among BCG-Bulgaria
group (Table 5.1), the magnitudes of CD4 cytokine responses were first stratified
by HIV exposure group and response magnitudes were compared by BCG strain
(Figure 5.2 & Table 5.2). Total CD4 cytokine response magnitudes were comparable
between strains before vaccination in both HIV exposure groups (Figure 5.2B).
At week 7 post BCG vaccination, however, the BCG-Denmark strain vaccinated
infants had higher frequencies of CD4+ cytokine-producing cells over background
(HEU median=0.77%, HU median=1.01%) compared to both Jos infants vaccinated
with BCG-Bulgaria (HEU median=0.45%, p=0.09; HU median=0.16%, p<0.0001
respectively) and CT infants vaccinated with BCG-Russia (HEU median=0.19%,
p<0.0001; HU median=0.05%, p<0.0001 respectively: Figure 5.2 and Table 5.2).
Of note was that infants from the same cohort but receiving different BCG strains
at birth showed significant differences in the magnitudes of responses. CT infants
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vaccinated with BCG-Denmark had higher cytokine+ frequencies compared to
those vaccinated BCG-Russia regardless of HIV exposure status at week 7 (5.2B).
A trend in these within-cohort differences extended to weeks 15 and 36 however
did not pass significance after adjustment for multiple comparisons (Table 5.2).
Examining longitudinal data from matched samples across all time points further
emphasised that infants vaccinated with BCG-Denmark, peaked at week 7 (Figure
5.2C), continued to express significantly higher CD4 cytokine responses compared
to BCG-Russia vaccinated infants at week 15 (median=0.40 vs. 0.17, p=0.03) and
week 36 (median=0.23% vs. 0.05%, p=0.006; Figure 5.2C). These results suggest
that BCG immunising strain impacts on the magnitude of mycobacterial response


































































































































































































































Figure 5.2: Magnitude of myco-bacterial CD4 cytokine responses differ by BCG strain. A & B: Cross-sectional analysis
of mycobacterial-specific CD4 cytokine responses between cohorts (A): irrespective of BCG immunising strain, (B)
between BCG immunising strain stratified by HIV exposure. Weeks indicate weeks post vaccination with week
0 being the pre-vaccination time point (birth for the CT cohort and a median of 4-7 days after birth for the Jos
cohort). Y axes show the frequencies (%) of CD4+ cells producing total cytokine (any combination of IFN-γ, IL-2 or
TNF-α). Shaded bars show the median value of cytokine+ cells in unstimulated samples. Boxes with mid-line show
interquartile ranges and median. (C) Longitudinal responses to BCG in samples matched for at least 3 time points
between week 0 and 36, stratified by BCG strain. Wilcoxon Rank Sum Test was used to compare cross-sectional
data, with p-values <0.001 considered significant after adjustment for multiple comparisons. Kruskal Wallis test
was applied to test for differences over time for longitudinal data.
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Table 5.2: Magnitude of mycobacterial-specific CD4 cytokine responses by BCG strain
Median CD4 cyk (IQR) p-values
Time Exposure Bulgarian Danish Russian B-D D-R B-R
0 HEU 0.09 (0.07-0.1) 0.04 (0.03-0.06) 0.09 (0.05-0.13) 0.08 0.03 1
7 0.45 (0.17-1.07) 0.77 (0.48-1.46) 0.19 (0.1-0.46) 0.09 <.001 0.12
15 0.22 (0.11-0.4) 0.47 (0.22-0.65) 0.17 (0.09-0.25) 0.03 <.001 1
36 0.14 (0.12-0.24) 0.2 (0.09-0.37) 0.08 (0.05-0.15) 0.8 0.01 0.04
0 HU 0.1 (0.06-0.23) 0.04 (0.03-0.08) 0.06 (0.03-0.11) 0.12 0.92 0.33
7 0.16 (0.14-0.29) 1.01 (0.4-1.28) 0.05 (0.04-0.12) <0.001 <.001 0.01
15 0.24 (0.11-0.46) 0.41 (0.2-0.7) 0.08 (0.03-0.17) 0.18 0.02 0.17
36 0.2 (0.14-0.28) 0.22 (0.16-0.52) 0.05 (0.04-0.09) 0.68 <.001 <.001
Numbers represent median frequencies of CD4+ cells producing total cytokine (any combination of IFN-γ, IL-2 or
TNF-α) with interquartile ranges in brackets. Time is expressed as weeks post BCG vaccination with week 0 the
pre-vaccination time point (birth for BCG-Denmark and BCG-Russia, and Week 1 after birth for BCG Bulgaria).
Wilcoxon Rank Sum Test was used to compare strains (B-D; Bulgarian vs. Danish, D-R; Danish vs. Russian, B-R;
Bulgarian vs. Russian) with P<0.001 significant after multiple comparison using Holm’s step down method.
5.3.3 Polyfunctional mycobacterial responses differ between strains
When examining the combinations of cytokines (IFN-γ, IL-2 and TNF-α) induced
by in vitro mycobacterial antigen stimulation by BCG strain, irrespective of HIV
exposure status, we observed that fewer polyfunctional (triple cytokine positive)
cells were induced among infants receiving BCG-Bulgaria. The majority of the
total response in BCG-Bulgaria immunised infants was single positive for IFN-
γ (Figure 5.3A & B). Conversely, infants receiving BCG-Denmark had a higher
proportions of CD4 cells expressing all three cytokines. This polyfunctional profile
was sustained from 7 to 36 weeks constituting more than a quarter of the total
cytokine response (median IFN-γ+IL-2+TNF-α+ at week 7 = 28%, week 15 = 26%,
week 36 = 27%). The proportions of these triple positive cells were significantly
lower for BCG-Bulgaria and BCG-Russia immunised infants (median at week 7 =
0% and 6%, respectively, p<0.001, week 15 = 0% and 7% respectively, p<0.001,
week 36 = 0% and 7%, respectively, p<0.001). Furthermore, the proportion of
dual-expressing IFN-γ+ and IL-2+ CD4+ T cells was higher among BCG-Denmark
recipients compared to BCG-Russia recipients (week 7 = 3% vs. 0% respectively,
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p<0.001) while the proportion of single TNF-α+ cells was lower (median at week
7 = 7% vs. 42%, p<0.001). When infants were further stratified by HIV exposure
status, the differences of cytokine profiles induced by BCG strains was still evident
BCG as shown in the example of week 7 responses (Figure 5.3C). To summarise,
SPICE analyses revealed polyfunctional and dual functional cytokine profiles induced
by myco-bacterial antigen stimulation that were significantly over-expressed by
BCG-Denmark immunised infants compared to both BCG-Bulgaria and BCG-Russia
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Figure 5.3: Cytokine profiles of mycobacterial-specific responses differ between BCG strains irrespective of HIV exposure
status. (A) Representative flow cytometry plots showing mycobacterial-specific antigen responses stratified by BCG
immunising strain. Axes show IFN-γ vs. TNF-α expression with IL-2+ cells overlaid and represented by blue dots.
(B) Jitter points show the median proportion of each cytokine combination (G=IFN-γ, 2=IL-2, T=TNF-α) per
infant as a fraction of total cytokine+ cells per infant responding to BCG irrespective of HIV exposure and are
colour-coded by BCG immunising strain (green = Bulgaria, blue = Denmark, orange = Russia) status. Shaded bars
show interquartile ranges with line showing median. Wilcoxon Rank Sum test was used to compare BCG strains vs.
BCG-Denmark, p<0.01 were considered significant after adjustment for multiple comparisons ***p<0.001, **p<0.01,
*p<0.05. Pie charts are a summary of the median proportions of cytokine combinations (G = IFN-γ, 2 = IL-2, T
= TNF-α) as a fraction of the total response in each BCG strain group irrespective of HIV exposure status by
SPICE analysis. Pie charts are compared using the SPICE permutations test with p<.01 considered significant. (C)
Pie charts summarising week 7 cytokine profiles by HIV exposure status and BCG immunising strain. (D) Week
7 polyfunctional and functional scores to BCG by BCG immunising strain. Scores are stratified by HIV exposure
status.
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SPICE analyses (Figure 5.3) was complimented with COMPASS [289], a statistical
tool that allows for the analysis of antigen-specific subsets in an unbiased manner.
The COMPASS model calculates posterior probabilities for each observed cytokine
subset, selecting those most likely to be antigen specific. In addition, the COMPASS
algorithm evaluates a polyfunctional score (PFS) for each participant which is, a single
statistic summarising a participant’s entire functionality profile [289]. PFS are defined
as the proportions of antigen-specific subsets detected amongst all possible subsets
and weighted towards those with higher functionality (2 or more cytokines) [289].
We first grouped infants by BCG immunising strain irrespective of HIV exposure
status and a heatmap of posterior probabilities for cytokine subsets were plotted and






























































































































Figure 5.4: Polyfunctional and functional scores to BCG by COMPASS analysis differ between BCG strains. (A) Heatmap
of posterior probabilities of mycobacterial-specific responses estimated by COMPASS analysis. Rows represent
individual infants and grouped by BCG immunising strain and time post BCG vaccination (colour-coded annotations
on right side of heat map). Columns represent cytokine subsets (combinations) ordered by degree of functionality
(single to polyfunctional; right to left). The colour of each cell corresponds to the probability (range 0-1) of a
mycobacterial-specific response for a particular cytokine cell subset per infant, with 1 indicating an antigen-specific
response and white indicating background. (B) Cross-sectional analysis of Polyfunctional scores (as calculated
in COMPASS model) stratified by BCG immunising strain [Green (BCG-Bulgaria), blue (BCG-Denmark), orange
(BCG-Russia)]. (C) Correlation between Polyfunctional scores and cytokine response magnitude. Spearman’s ranked
correlation coefficient is reported for n=109 infants in all BCG strain groups. Mann Whitney U test was used to
test for differences by BCG strain. P<.001 were considered significant after multiple adjustment correction using
Holm’s step-down method.
In the heatmap we observed that BCG-Denmark infants had more antigen-specific
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polyfunctional and dual functional responses compared to either BCG-Russia and
BCG-Bulgaria recipients. When comparing polyfunctional scores by strain (Figure
5.4B), as expected these were not different among the BCG strains at the pre-
vaccination time point (week 0), however BCG-Denmark immunised infants had
PFS that were statistically significant at week 7 compared to the other strains
(median BCG-Denmark PFS = 0.9 vs. BCG-Bulgaria = 0.15 (p<.001), BCG-
Russia = 0.29 (p<.001)). This trend remained until week 36 were BCG-Denmark
immunised infants continued to display higher median PFS than the other strains.
Furthermore, polyfunctional scores were significantly correlated with the magnitude
of mycobacterial responses suggesting that the higher total cytokine induced by
BCG, the more likely the participant had a polyfunctional response (Figure 5.4C).
This more unbiased approach to measuring Th1 polyfunctionality is compatible with
our SPICE analyses (Figure 5.3B) and shows that BCG-Denmark elicits a more
functional immune response in the newborn infant. We also evaluated polyfunctional
scores by BCG immunising strain, but stratified by HIV exposure status (Figure
5.3D). At week 7 post BCG, both HEU and HU polyfunctional scores to BCG
were equally affected by the immunising strain. Collectively, these data show that
BCG-Denmark is more immunogenic than BCG-Bulgaria and BCG-Russia strains,
characterised by a higher magnitude of response and a more polyfunctional cytokine
profile.
5.3.4 BCG-Denmark induces a more differentiated memory pheno-
type compared to other strains
To better understand whether BCG-Denmark may result in a more mature antigen-
stimulated CD4+ T cell memory differentiation, which along with greater poly-
functionality provides important insight into protective responses against infec-
tions [290, 136], the memory phenotypes of the total cytokine BCG responding cells
(i.e. cytokine positive) defined as naïve (CD27+CD45RA+), early differentiated
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(ED, CD27+CD45RA-), late differentiated (LD, CD27-CD45RA-) and terminally
differentiated (TD, CD27-CD45RA+) CD4+ T cells. Our analysis of these sub-
sets was restricted to only those infant cells that responded to BCG (above 2-fold
background). A large population of cytokine positive cells with a naïve phenotype
(CD27+CD45RA+) was evident, which we hereon refer to as naïve-like (Figure 5.5).
Although there was a large range in the frequency of cytokine expressing memory
cell subsets, we consistently observed that BCG-Denmark induced a lower frequency
of these naïve-like cells across all time points post BCG vaccination. BCG-Denmark
induced a predominantly ED profile, particularly at week 15 where BCG-Denmark
induced the lowest frequencies of CD4+ cytokine positive cells expressing naïve-like
markers (median = 22%) compared to BCG-Bulgaria and BCG-Russia (median =
40% and 36%; p=0.02 and p=0.04, respectively). Conversely, the CD4+ cytokine
positive cells expressing ED markers were highest among BCG-Denmark vaccinated
infants (median = 53%) compared to BCG-Bulgaria and BCG-Russia (37% and
33%; p=0.03 and p=0.04, respectively). Collectively, these data suggest that BCG-
Denmark pushes cells into more differentiated memory state, which may explain
the higher magnitude and polyfunctionality of response. Conversely, vaccination






















































































Figure 5.5: BCG-Denmark induces a more differentiated T cell memory phenotype compared to BCG-Russia or BCG-
Bulgaria strains. Frequency of mycobacterial-specific memory subsets stratified by BCG immunising strain. Data
point colors: Green (BCG-Bulgaria), blue (BCG-Denmark), orange (BCG-Russia), show the proportion of cytokine+
cells co-expressing combinations of memory markers CD45RA and CD27 that define memory subsets (as described
in Figure 7.6). Wilcoxon Rank Sum Test was used to test for differences by BCG strain. P<0.001 were considered
significant.
5.3.5 Strain of BCG impacts CD4+ responses to heterologous anti-
gens
Given that BCG has been shown to have heterologous effects to non-BCG antigens
[285, 145], we examined the effect of BCG strain on CD4+ T cell responses to TT,
BP and PHA (Table 5.3 and Figures 5.6 & 5.7). We focused only on CT infants
and compared those who received BCG-Denmark versus BCG-Russia strains, and
thus removed the potential confounding effects of geography, genetic background of
participants and different vaccination strategies. When stratified by HIV exposure
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status, an interesting pattern was observed: differences in the magnitudes of CD4
cytokine responses to heterologous antigens (TT, BP and PHA) were most apparent
the HEU group (Table 5.3 and Figure 5.6). Specifically at week 15 post BCG, HEU
infants receiving BCG-Denmark strain had significantly higher responses than those
receiving BCG-Russia (TT median= 0.26% vs. 0.05%, p<0.001; BP median = 0.14%
vs. 0.06%, p=.002; PHA median = 0.86% vs. 0.18%, p=0.003, respectively). Among
HU infants the most significant difference was observed at week 7 for responses to
TT, where BCG-Denmark induced higher responses compared to BCG-Russia (TT
median= 0.1% vs. 0.02%, p=0.001, respectively) and to a lesser extent week 15
responses to PHA (PHA median = 0.73% vs. 0.15%, p=0.007), though this did
not hold after adjustment for multiple comparisons. These results suggest that the



























































































Figure 5.6: BCG immunising strain impacts the magnitude of heterologous antigen responses. Cross-sectional analysis of
heterologous antigen-specific CD4 cytokine responses between BCG-Denmark vs. BCG-Russia immunised infants.
A: Responses among HEU groups. B: Responses among HU groups. Weeks indicate the time point post BCG
vaccination. Y axes show the frequencies (%) of CD4+ cells producing total cytokine (any combination of IFN-γ,
IL-2 or TNF-α). Shaded bars showing median value of unstimulated samples. Wilcoxon Rank Sum Test was used
to compare cross-sectional data, with p values <0.01 were significant after adjustment for multiple comparisons.
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Table 5.3: Magnitudes of heterologous antigen responses by BCG immunising strain
Median CD4 cyk (IQR)
Age (weeks) Exposure Antigen Danish Russian P-values
7 HEU TT 0.11 (0.05-0.18) 0.07 (0.04-0.12) 0.125
BP 0.12 (0.08-0.18) 0.07 (0.05-0.11) 0.021
PHA 0.89 (0.15-4.04) 0.61 (0.14-2.38) 0.332
15 TT 0.26 (0.15-0.39) 0.05 (0.05-0.07) <.0001
BP 0.14 (0.09-0.23) 0.06 (0.04-0.09) 0.002
PHA 0.86 (0.27-2.87) 0.18 (0.09-0.25) 0.003
36 TT 0.15 (0.07-0.26) 0.06 (0.05-0.12) 0.029
BP 0.1 (0.06-0.19) 0.1 (0.06-0.15) 0.614
PHA 0.24 (0.05-1.45) 0.11 (0.06-0.23) 0.252
7 HU TT 0.1 (0.05-0.17) 0.02 (0.01-0.03) 0.001
BP 0.11 (0.06-0.15) 0.03 (0.02-0.04) 0.012
PHA 1.56 (0.18-5.56) 0.06 (0.04-1.48) 0.108
15 TT 0.11 (0.06-0.26) 0.1 (0.07-0.12) 0.515
BP 0.08 (0.07-0.17) 0.08 (0.05-0.1) 0.398
PHA 0.73 (0.32-2.09) 0.15 (0.12-0.26) 0.007
36 TT 0.14 (0.09-0.34) 0.03 (0.03-0.11) 0.027
BP 0.11 (0.08-0.16) 0.06 (0.04-0.08) 0.036
PHA 0.94 (0.15-3.06) 0.13 (0.05-0.42) 0.026
BCG-Denmark and BCG-Russia were infants from the Cape Town cohort. Numbers represent median frequencies
of CD4+ cells producing total cytokine (any combination of IFN-γ, IL-2 or TNF-α) with interquartile ranges in
brackets. Time is expressed as weeks post BCG vaccination with week 0 the pre-vaccination time point (birth for
BCG-Denmark and BCG-Russia, and Week 1 after birth for BCG Bulgaria). Wilcoxon Rank Sum Test was used to
compare strains (B-D; Bulgarian vs. Danish, D-R; Danish vs. Russian, B-R; Bulgarian vs. Russian) with p<0.005
significant after multiple comparison using Holm’s step down method.
We examined the cytokine profiles of these responses at week 7, when the BCG
response itself peaked. At this time point the most significant differences in cytokine
profiles to heterologous antigens between BCG immunising strains was observed
and are shown in Figure 5.7. BCG-Denmark strain induced significantly higher
proportions of polyfunctional (IFN-γ+ and TNF-α+ and IL-2+) CD4 cells to TT
(median = 1.7% vs. 0%, p=0.001), BP (1.6% vs. 0%, p<.0001) and dual-functional
(TNF-α+ and IL-2+) to PHA (16.2% vs. 2.6%, p<.0001) (Figure 5.7B). In addition,
lower proportions of single TNF-α+ responding CD4+ T cells among BCG-Denmark
immunised infants compared to BCG-Russia for TT (median = 14.1% vs. 39.6%,
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Figure 5.7: Cytokine profiles to heterologous antigens at week 7.(A) Representative flow cytometry plots showing
heterolgous antigen responses (TT: Tetanus Toxoid, BP: Bordetella Pertussis, PHA: Phytohaemagluttinin) stratified
by BCG immunising strain. Axes show IL-2+ vs. TNF-α and IFN-γ overlaid in blue dots. (B) Jitter points show
the median proportion of each cytokine combination (G = IFN-γ, 2 = IL-2, T = TNF-α) per infant as a fraction of
total cytokine+ cells per infant responding to TT, BP and PHA and are colour-coded by BCG immunising strain
(blue = Denmark, orange = Russia) irrespective of HIV exposure status. Shaded bars show interquartile ranges
with line showing median. Wilcoxon Rank Sum test was used to compare BCG strains, P<0.05 were considered
significant ***P<0.001, **P<0.01, *P<0.05. Pie charts are a summary of the median proportions of cytokine
combinations (G = IFN-γ, 2 = IL-2, T = TNF-α) as a fraction of the total response in each BCG strain group
irrespective of HIV exposure status by SPICE analysis. Pie charts are compared using the SPICE permutations
test with P<.01 considered significant.(C) Pie charts summarising week 7 cytokine profiles by HIV exposure status
and BCG immunising strain.
When stratified by both BCG strain and HIV exposure, the impact of strain
was still evident for these heterologous antigens (Figure 5.8), where differences in
the cytokine profiles occurred equally for both HEU and HU infants. Interestingly,
cytokine profiles did not differ beyond week 7 post BCG (data not shown), suggesting
that the heterologous effects of BCG strain on the types of cytokines induced occurs
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short-lived. Collectively, our data show that the strain used for BCG vaccination has
a profound impact on the magnitude and polyfunctionality of CD4+ T cell responses




















































































































































Figure 5.8: BCG immunising strain impacts on heterologous antigen responses: polyfunctional and functional scores by
COMPASS. Cross-sectional analysis of heterologous antigen polyfunctional (A, C, E) and functional scores (B, D,
F) between BCG-Denmark vs. BCG-Russia immunised infants. Scores are stratifed by HIV exposure status (HEU:
HIV-exposed and uninfected and HU: HIV-unexposed). A & B (BCG scores), C & D (Tetanus Toxoid scores), E
& F (Bordetella pertussis scores). Weeks indicate the time point post BCG vaccination. Y axes show the score




This chapter shows that the magnitude and polyfunctional nature of CD4+ T cell
responses to BCG and other heterologous antigens in the first few months of life
depends on the immunising strain of BCG itself irregardless of HIV exposure status.
BCG-Denmark is the most immunogenic compared to BCG-Russia and BCG-Bulgaria
strains and causes an early differentiated phenotype in memory CD4+ T cells. The
latter strains appear to allow the accumulation of naïve-like responsive cells, which
appear to induce mono-functional responses. The important aspect of our study is
that responding CD4+ T cells to all vaccine antigens, including Tetanus and Pertussis,
were significantly affected by the strain of immunising BCG, with the Denmark
strain inducing the highest magnitude of responses and a Th1 polyfunctional subset.
Furthermore, the relatively advanced stage of CD4+ T cell memory maturation in
response to BCG-Denmark may explain the phenomena of infant cells responding
with greater magnitude and Th1 polyfunction. We acknowledge that this was purely
an observational study, and a confirmatory study in the form of a randomised control
trial is needed. Both specific and non-specific immune responses to the BCG vaccine
by strain have been shown in a randomised control trial [286], however long-term
culture assays were used to measure cytokine in culture supernatant—which does
not inform the cellular source of the response. Here we identify T cells as being part
of the effector response that defines differences in antigenicity across BCG strains.
Prior studies have suggested that BCG-Denmark may be more immunogenic
than other widely available BCG strains. A randomised control trial in Uganda
administering the same BCG strains used in this study showed that BCG-Denmark
induced the highest levels of IFN-γ, IL-13 and IL-5 in culture supernatants to BCG,
TT and PHA stimulation [286]. The cellular source of cytokine production, however,
was not measured due to the nature of the assay used. In support of our data, CD4
polyfunctionality among infants randomised to receive BCG-Denmark, -Japan and
-Russia at birth showed higher polyfunctional (IFN-γ+TNF-α+IL-2+) responses
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after BCG-Denmark strain immunisation [281]. Our findings are similar, except that
our cohorts are in some of the highest TB endemic areas in Africa [194, 186, 126,
106] and that the early differentiated memory state may also be important for the
heterologous non-BCG antigen effects we observe with BCG-Denmark. Although
CD4+ Th1 cytokine responses are not cognate correlates of protection against Tetanus
and Pertussis, they are likely important measures of overall immune responsiveness
to heterologous antigens. BCG itself has well documented "training" effects where
enhanced monocyte mediated responses against other pathogens are central [291,
285]. The molecular mechanisms are thought to include recognition by the NOD2
receptor in monocytes, the induction of pro-inflammatory cytokines—3 months after
vaccination—and the epigenetic reprogramming of monocyte populations [117, 285].
Heterologous effects of BCG vaccination on Th1 and Th17 immunity have been
shown to persist for up to a year after vaccination [287]. The immunological basis for
different heterologous effects by BCG strain is not known. The attenuation of BCG
is the result of the loss of virulent elements in the genome, with some strains having
more regions of deletions than others [292, 280, 293]. BCG-Denmark, a member of
the DU2-III group, has more deletions than both BCG-Russia and BCG-Bulgaria
from group DU2-I [280]. The better quality and quantity of responses induced by
BCG-Denmark are unlikely-related to antigenic coverage as this strain has less T cell
epitopes than BCG-Russia [293]. Certain BCG strains are known to replicate and
persist longer in tissues after immunisation in animal models [294, 277] and this may
result in different antigen priming between strains. However, there are most likely
numerous factors other than antigen load, as BCG-Russia has been found to replicate
and persist in tissues of immunised mice over and above BCG-Denmark related
strains (BCG-Prague and BCG-Glaxo strains) [294]. There are likely numerous
possible reasons for differences in vaccine immunogenicity between CT and Jos.
We do not regard the six-fold lower CFU dose of BCG-Bulgaria, compared with
BCG-Denmark/Russia, as a contributing factor (Table 7.3). Suboptimal vaccination
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doses affect the magnitudes of Th1 responses in adults [295], but not infants [296].
Differences in immune responses between cohorts may also depend on population
differences; i.e. environmental antigen exposure and/or genetics [276, 17, 32]. For
example helminth and malaria co-infections, which are common in Nigeria, are
associated with IL-10 responses and a skewing to Th2 response to Mtb [40], but
we did not evaluate helminth infections in our infant cohort. Shipping of cells
from Nigeria to South Africa may have impacted on their integrity. However, our
finding that BCG-Russia—which is closely related to BCG-Bulgaria [297]—also
resulted in a similar set of low magnitude and polyfunctional responses in CT
infants led us to regard BCG strain differences as a main determinant of vaccine
immunogenicity. Finally, although the proportion of HIV-exposed infants was
unbalanced between the groups, this would have favoured better responses in the
BCG-Bulgarian infants. In 2016, many countries around the world experienced a
shortage of BCG-Denmark and had to transition to other strains [298]. Our results
suggest that BCG vaccination, given to over 100 million infants annually around the
globe, has variable immunogenicity according to strain, and that heterologous effects
may be specific to BCG-Denmark. We do not discount the possibility that differences
between strains may be related to the number of live replicating bacilli—which may
be different across manufacturers. These findings have implications for vaccine policy
makers, manufacturers and programs worldwide. These findings also suggest that
BCG-Denmark, the first vaccine received in many African infants, has both specific
and non-specific heterologous effects to HEUs in the first few months of life, and




Thesis summary and conclusions
Birth
HEU
wk1 wk7 wk15 wk36
HU
Birth wk1 wk7 wk15 wk36
Activated T cell Maternal pro-inflammatory 
cytokines
Maternal and infant 

antiretrovirals













Figure 6.1: Synopsis of thesis. We hypothesised that as a result of exposure to maternal
pro-inflammatory signals and ART drug regimens in utero and postpartum, the immune
milieu of children born to HIV infected mothers (cHEU) is (i) activated, (ii) has an altered
transcriptional profile and (ii) is functionally perturbed in response to vaccination. At
birth, two gene homologues synonymous with cellular stress were increased in peripheral
blood among HEUs, with no significant enrichment or suppression of biological pathways.
For BCG vaccine moderate differences in single cytokine producing cells were observed one
week after vaccination in those with detectable immune responses. Later however (weeks
7-36), BCG immunity was indistinguishable from un-exposed infants in both magnitude and
polyfunctional phenotypes concomitant with hypothesized lower ART exposure (neonatal
and via breast milk). Most activated T cell phenotypes followed similar kinetics, however
increased activated CD8 T cells (expressing CD25 or HLA-DR) were elevated in HEUs
and in particular at week 36 of age.
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6.1 Thesis summary
This thesis began in Chapter 2 with the exploration of possible transcriptomic
signatures in blood that distinguish cHEU from cHU controls at birth. A small
set of differentially expressed genes were identified but did not translate to any
differences in gene pathways in the HEU. We then explored the hyothesis that cHEUs
would have different frequencies of activated, proliferating or gut homing T cells
compared to HU in Chapter 3. On the whole, the kinetics in the frequencies of T cell
phenotypes followed similar patterns of peaking and waning between HIV exposure
groups between birth and 36 weeks. Two markers were significantly increased in CD8
T cells of HEU across all time-points: HLA-DR and CD25, the latter significantly
at 36 weeks in cross-sectional analyses. In Chapter 4, we explored whether T cell
function was perturbed in the HEU by analysing the magnitudes and cytokine profiles
of T cells responding to vaccine antigen using a short-term in vitro assay. There
was a trend towards differences in quality of vaccine-specific T cell responses by
HIV exposure status, depending on the stimulating antigen, however these did not
hold when applying the more robust COMPASS algorithm. Two key observations
prompted a further interrogation of BCG responses and was the focus of Chapter 5:
(i) BCG response magnitudes were differed by cohort site and (ii) CT infants had been
vaccinated with one of two strains of BCG (Denmark or Russian), whereas Jos infants
had received the Bulgarian strain—genetically identical to the Russian strain. We
hypothesized that the immunising strain of BCG resulted in different BCG response
profiles and therefore stratified BCG response magnitudes and cytokine profiles to
the strains used to immunise infants. BCG-Denmark immunisation in CT infants
resulted in higher mycobacterial-specific CD4 responses with greater polyfunctional
profiles and more memory differentiated BCG-specific phenotype compared to either
CT infants receiving BCG-Russia or Jos infants receiving BCG-Bulgaria strains.
Furthermore, there were heterologous effects of BCG Denmark, meaning that this
immunogenic strain extended to boosting the non-mycobacterial antigens of TT
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and BP (as well as the PHA positive control stimulus). These observations were
independent of HIV exposure status.
6.1.1 Limitations of the study
A major limitation of this study was the use of whole blood to address the thesis
aims regarding immune ontogeny in the HEU infant. Peripheral blood is relatively
non-invasive can be cryopreserved for batch measurements and has a wide range
of commercially available reagent toolkits. There is however, discordance between
peripheral blood and sites of infection/disease in terms of immune subsets, functional
profiles, differentiation states and thresholds for antigenic stimulation [299, 300, 301,
302, 303]. Another limitation was that flow cytometry design constraints only allowed
us to measure Th1 cytokines in our whole blood assay. Given Th2 skweing in early
life [1] and that all antigens in this study can induce Th2 responses [276, 304], we
missed a more comprehensive evaluation of T cell function in the HEU. In addition,
some samples from the Jos cohort were compromised, possibly during shipping or
due to technical error during processing. This limited our sample sizes from this
cohort in some assays.
6.1.2 Concluding remarks
The sites in which these study cohorts were derived have extensive HIV care, coun-
selling and management services for women during pregnancy and post-partum
[305, 306]. Both have implemented WHO’s Option B+ which is lifelong care for
all HIV pregnant women regardless of CD4 count. In addition, maternal breast
feeding rates among HIV infected women were high in both sites [98], meaning that
HIV exposed babies benefited from nutrition and passive immunity provided by
breast-milk. Therefore, our study populations may represent some of the ‘healthier’
HIV exposed infant cohorts compared to previous cohorts [307]. Equal rates of
infectious morbidities between HEU and HU groups were previously demonstrated in
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the same cohorts used here (hazard ratio 1.01; 95% CI 0.78 - 1.32) [98]. Thus, in the
context of our specific cohort, this thesis can surmise that: (i) in utero ART/HIV
exposure does not perturb immune pathways HEU newborn, (ii) ART/HIV exposure
does not significantly alter vaccine-specific T cell responses over the first 9 months
of life, (iii) ART/HIV exposure induces an activated T cell phenotype compared to
un-exposed controls during the first 9 months of life.
The negative results for gene transcription and functional immunity presented
here demonstrate that effective ART has no deleterious consequences for the general
immune biology in the HEU and results in a parity of T cell vaccine immunity
with unexposed infants. We rather showed that the immunising strain of BCG
had significant mycobacterial and off-target effects in the HEU. The effect of BCG
"trained immunity" to off-target has been well-documented in animal and human
models [285, 308, 287, 309]. Whether the strain of BCG administered will ultimately
mean disproportionate levels of protection to other infections in HEU can only be
determined by large, randomised control trials with well-defined clinical endpoints.
Our observation that bulk CD8 cells from HEUs have an activated phenotype relative
to HUs is in line with previous reports on activated immune subsets in HEUs (Table
3.5). This warrants further investigation as to the underlying mechanisms and in
vitro experiments where PBMCs would be exposed to escalating doses of ART, for
example, could partially address this. Importantly, whether in vivo CD8 activation
levels represent a correlate of infection risk in HEUs beyond the first year of life
should be investigated in observational studies. Overall, this thesis provides evidence
for immune competence in our cohorts and demonstrates how beneficial Option B+
is to the health of infants during the first year of life.
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Combined study participant characteristics
HEU, N=137 HUU, N=57 P-values
Infant
Gestation, weeks 38 (37 - 39) 38 (38 - 39) 0.55
Birth weigh, g 3025 (2778 - 3330) 2930 (2840 - 3230) 0.95
Length, cm 48 (46 - 50) 48 (47 - 50) 0.40
% Female 58 32 0.20
Maternal
Weight, kg 70 (63 - 79) 70 (63 - 75) 0.55
Age, years 29 (25 - 33) 26 (23 - 30) 0.05
CD4, cells/mL 447 (316 - 561) n/a
% EBF to 6 months 81 88 0.18
Numbers indicate median and (IQR) unless otherwise stated. P-values calculated using Wilcoxon Rank Sum test.
Chi-squared test of homogeneity was used to compared distribution of gender and exclusive breastfeeding rates (%














































































































































































































Figure 7.2: T cell markers of activation, proliferation and gut homing in Jos infants. Ex
vivo markers in matched samples were measured from birth to 36 weeks for cHEU (maroon
circles, N=11) and cHU (grey circles, N=16) and are expressed as a percentage of the
parent T cell population (CD4 or CD8). A4B7 = α4β7. CCR5hiA4B7hi= CCR5hi+α4β7hi
(potential HIV target cells). CD25 were CD127hi and Treg-like cells were CD25+CD127lo.
A paired Wilcoxon Ranked sum test was used to compare expression between CD4 and
CD8 populations. P values<0.001 were significant after adjusting for multiple comparisons
using the Holm’s step down method.
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Table 7.2: Results of post-hoc Friedman test comparing expression of T cell markers
between time intervals
CD4+ Age interval group 1 p-adj 1 group 2 p-adj 2 CD8+ Age interval group 3 p-adj 3 group 4 p-adj 4
CCR5hi 0-7 HEU 0.02 HU <0.001 0-7 HEU 0.06 HU 0.06
0-15 HEU 0.02 HU 0.08 0-15 HEU 0.03 HU 0.001
0-36 HEU 0.003 HU 0.19 0-36 HEU 0.006 HU 0.26
15-36 HEU 0.94 HU 0.98 15-36 HEU 0.94 HU 0.22
7-15 HEU 1 HU 0.35 7-15 HEU 1 HU 0.57
7-36 HEU 0.94 HU 0.19 7-36 HEU 0.87 HU 0.92
CD25 0-7 HEU NA HU NA 0-7 HEU 0.14 HU NA
0-15 HEU NA HU NA 0-15 HEU 0.65 HU NA
0-36 HEU NA HU NA 0-36 HEU 0.02 HU NA
15-36 HEU NA HU NA 15-36 HEU 0.77 HU NA
7-15 HEU NA HU NA 7-15 HEU 0.87 HU NA
HLA-DR 0-7 HEU NA HU 0.01 0-7 HEU 0.06 HU 0.30
0-15 HEU NA HU 0.19 0-15 HEU 0.09 HU 0.02
0-36 HEU NA HU <0.001 0-36 HEU 0.001 HU 0.04
7-15 HEU NA HU 0.69 15-36 HEU 0.52 HU 1
7-36 HEU NA HU 0.80 7-15 HEU 1 HU 0.63
15-36 HEU NA HU 0.19 7-36 HEU 0.65 HU 0.80
7-36 HEU NA HU . 0.80 7-36 HEU 0.30 HU 0.80
Ki67 0-7 HEU 0.02 HU 0.003 0-7 HEU NA HU NA
0-15 HEU 0.01 HU 0.26 0-15 HEU NA HU NA
0-36 HEU 0.004 HU 0.80 0-36 HEU NA HU NA
15-36 HEU 0.98 HU 0.80 15-36 HEU NA HU NA
7-15 HEU 1 HU 0.35 7-15 HEU NA HU NA
7-36 HEU 0.96 HU 0.05 7-36 HEU NA HU NA
HLA-DR+Ki67+ 0-7 HEU 0.03 HU 0.001 0-7 HEU 0.14 HU 0.03
0-15 HEU 0.003 HU 0.05 0-15 HEU 0.001 HU <0.001
0-36 HEU 0.007 HU 0.02 0-36 HEU 0.006 HU 0.02
15-36 HEU 1 HU 0.98 15-36 HEU 0.94 HU 0.58
7-15 HEU 0.90 HU 0.69 7-15 HEU 0.30 HU 0.46
7-36 HEU 0.96 HU 0.89 7-36 HEU 0.65 HU 1
α4β7hi 0-7 HEU 0.042 HU 0.13 0-7 HEU 0.02 HU NA
0-15 HEU 0.13 HU 0.26 0-15 HEU 0.41 HU NA
0-36 HEU 0.01 HU 0.002 0-36 HEU 0.06 HU NA
15-36 HEU 0.82 HU 0.26 15-36 HEU 0.53 HU NA
7-15 HEU 0.96 HU 0.98 7-15 HEU 0.98 HU NA
7-36 HEU 0.98 HU 0.46 7-36 HEU 0.77 HU NA
CCR5hi+α4β7hi+ 0-7 HEU 0.06 HU 0.01 0-7 HEU 0.04 HU 0.01
0-15 HEU 0.03 HU 0.08 0-15 HEU 0.06 HU 0.08
0-36 HEU 0.005 HU <0.001 0-36 HEU 0.001 HU 0.02
15-36 HEU 0.94 HU 0.19 15-36 HEU 0.59 HU 0.95
7-15 HEU 1 HU 0.89 7-15 HEU 1 HU 0.89
7-36 HEU 0.87 HU 0.58 7-36 HEU 0.65 HU 1
PD-1 0-7 HEU 0.53 HU 0.58 0-7 HEU 0.80 HU NA
0-15 HEU 0.006 HU 0.003 0-15 HEU 0.03 HU NA
0-36 HEU 0.001 HU 0.002 0-36 HEU 0.26 HU NA
15-36 HEU 0.94 HU 1 15-36 HEU 0.26 HU NA
7-15 HEU 0.21 HU 0.13 7-15 HEU 0.80 HU NA
7-36 HEU 0.06 HU 0.08 7-36 HEU 0.80 HU NA
Treg-like 0-7 HEU 0.06 HU 0.001 0-7 HEU ND HU ND
0-15 HEU 0.09 HU 0.08 0-15 HEU ND HU ND
0-36 HEU 0.002 HU 0.01 0-36 HEU ND HU ND
15-36 HEU 0.05 HU 0.89 15-36 HEU ND HU ND
7-15 HEU 1 HU 0.58 7-15 HEU ND HU ND
7-36 HEU 0.65 HU 0.95 7-36 HEU ND HU ND
P-adjusted values are post-hoc p-values following a Friedman test. Age intervals listed are in weeks. If overall





































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 7.4: Comparison of vaccine responses by cohort. Infants for each cohort were
grouped irrespective of HIV exposure. (A) BCG, (B) Tetanus Toxoid, (C) Bordetella
Pertussis and (D) PHA responses are shown for CD4 cells. A Wilcoxon Ranked Sum test
was applied to test differences by cohort and P<0.01 were considered significant after
multiple comparisons correction.
170
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Figure 7.5: Comparison of COMPASS polyfunctional scores for BCG responses. Infants
for each cohort were grouped irrespective of HIV exposure. A Wilcoxon Ranked Sum test
was applied to test differences by cohort. P<0.01 were considered significant after multiple
adjustment correction using Holm’s step down method.
Table 7.3: Vaccine and whole blood assay antigen dose
Cohort Vaccine dose In vitro antigen concentration
CT Denmark 1331 (∼2 x 105 CFU) Denmark 1331(∼12 x 105 CFU/mL)
Tetanus Toxoid (>40 IU) Tetanus Toxoid antigen (5 IU/mL)
Acellular Pertussis (25µg) Bordetella antigens (0.1%v/v)
Jos Bulgaria SL 222 Sofia (∼0.3 x 105 CFU) Bulgaria SL 222 Sofia (144 CFU/mL)
Tetanus Toxoid (>40 IU) Tetanus Toxoid antigen (5 IU/mL)
Whole cell Pertussis (>4.0IU) Bordetella antigens (0.1%v/v)
Numbers represent approximate in vivo vaccine dose per infant and in vitro antigen concentration per mL of whole





























Figure 7.6: BCG-Denmark induces a more differentiated T cell memory phenotype com-
pared to BCG-Russia or BCG-Bulgaria strains. Representative flow cytometry plots
showing the memory profile of mycobacterial-specific (cytokine positive) CD4 cytokine
responses stratified by BCG immunizing strain. Axes show CD27 vs. CD45RA expression
and blue dots are cytokine+ cells responding to BCG overlaid against a background of
total CD4+ cells. CD45RA+CD27+ represent naïve-like, CD45RA-CD27+ early differ-
























































































Proportion of antigen responders by BCG strain
Figure 7.7: Proportion of antigen responders by BCG immunising strain. Bar plots
show the frequency of responders defined as >2-fold above background (unstimulated
CD4+cytokine frequency) for each of the antigens measured in the whole blood assay.
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